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ABSTRACT 
INTERDEPENDENT REGULATION OF CYTOMEGALOVIRUS PROTEINS IN 
COMPLEX 
Lisa L. Bolin 
Eastern Virginia Medical School and Old Dominion University, 2009 
Director: Dr. Ann E. Campbell 
Human cytomegalovirus (HCMV) is a ubiquitous herpesvirus that causes 
significant morbidity and mortality in the immune compromised. Using the murine 
cytomegalovirus (MCMV) model,'we identified two genes, M140 and M141, which are 
determinants of macrophage tropism. Monocytes/macrophages are a critical cell type for 
cytomegalovirus (CMV) pathogenesis as sites of viral latency and by supporting viral 
replication and disseminating virus throughout the body. We previously found that the 
localization of the M140/M141 gene products (pM140/pM141) is different when the 
proteins are co-expressed as compared to their individual expression. When the proteins 
are individually expressed pM141 localizes diffusely throughout the cytoplasm and, to a 
lesser extent, the nucleus while pM140 localizes almost exclusively in the nucleus. Co-
expression alters the localization of either protein, as they co-localize to a distinct 
perinuclear region. The proteins form a stable complex and in the absence of pM140, 
pM141 is significantly destabilized. These results imply a complex regulation and 
interdependence of the proteins. 
The purpose of this study was to identify protein domains within pM140 and 
pM141 that are required for the interdependent regulation of the proteins and to 
determine the mechanism of pM141 protein degradation. We identified an interaction 
domain within pM140 at the extreme N terminus of the protein that is required foroptimal 
complexing with in vitro expressed pM141. We found that pM141 is degraded in a 
proteasome-dependent, but ubiquitin-independent pathway. The Ml41 protein is 
stabilized by pM140 in a concentration-dependent manner and we identified the region of 
pM140 required to stabilize pM141. However, direct complexing between pM140 and 
pM141 is not sufficient to stabilize the protein. Thus, our results support a model in 
which pM140 protects pM141 from proteasomal degradation by recruiting an additional 
viral or cellular protein to the pM140 and pM141 complex and this as yet unidentified 
protein is strictly required for pM141 stability. 
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The Family Herpesviridae 
Herpesviruses are widely distributed in nature and have been isolated from most 
animal species (150). Acute infection, accompanied by cytopathic effects, is followed by 
lifelong latency (150). The family Herpesviridae contains three subfamilies based on 
biological properties of the viruses. The alphaherpesvirinae contain members that 
establish latency in sensory ganglia and exhibit variable host range (150). Compared to 
other subfamilies, the alphaherpesvirinae have an abbreviated life cycle and rapidly 
destroy infected host cells (150). The subfamily is represented by viruses such as herpes 
simplex virus types 1 and 2, varicella-zoster virus, and feline rhinotracheitis herpesvirus. 
The betaherpesvirinae, to which human cytomegalovirus (HCMV) and murine 
cytomegalovirus (MCMV) belong, exhibit strict species-specificity and cause 
enlargement of infected host cells (150). Compared to other subfamilies the 
betaherpesvirinae have a long reproductive cycle (150). The gammaherpesvirinae, 
represented by members such as Epstein-Barr virus and Kaposi's sarcoma-associated 
herpesvirus, consist of viruses that typically exhibit limited host range and are 
lymphotropic with specificity for either T- or B-lymphocytes (150). 
CMV virion and genome 
The HCMV and MCMV virions are similar in structure (Fig. 1A (114)). The 
The model journal for this dissertation is Journal of Virology. 
linear, double-stranded DNA genome is enclosed in an icosahedral capsid composed of at 
least four viral proteins (85, 114, 176). The capsid is surround by a host cell-derived 
lipid membrane studded with numerous viral glycoproteins that serve as attachment 
proteins (114). Between the capsid and outer membrane is a tegument layer composed of 
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FIG. 1. CMV virion and genome. A. Diagram of a CMV virion. Arrows show the location of the 
glycoproteins, membrane, tegument, DNA, and capsid. B. Schematic representation of the HCMV and 
MCMV genomes. A scale is shown at top where each tick mark is 10 kbp. The HCMV genome (middle) 
is shown with the locations of the unique long (UL) and short (Us) regions as open boxes. The internal 
(IRL, IRS) and terminal repeats (TRL, TRS) are displayed as gray boxes. The MCMV genome (bottom) 
contains short terminal repeats (not shown), clusters of direct repeats (black lines where thickness 
represents relative cluster size), and inverted repeats (gray lines). 
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The genomes of HCMV and MCMV are similarly sized at just over 230 kilobase 
pairs (kbp) of DNA (Fig. IB (21, 143)). The HCMV genome is predicted to contain over 
200 open reading frames (ORFs) while the number of MCMV ORFs is predicted to be a 
little lower, at 170 (21, 37, 85, 116, 143, 201). The HCMV genome is composed of two 
unique segments designated UL (unique long) and Us (unique short) each flanked by a 
terminal repeat element (TRL or TRs) on one side and an inverted repeat (IRL or IRs) on 
the other side (114). The terminal repeat elements can isomerize giving rise to four 
genome arrangements (114). Nomenclature of HCMV ORFs is based on their location 
within the unique or repeated regions and within each region the ORFs are sequentially 
numbered (21, 169). The MCMV genome contains short terminal direct repeats as well 
as short internal direct repeats and inverted repeats throughout the genome that do not 
isomerize to generate additional sequence arrangements (38, 107, 143). MCMV ORFs 
are numbered sequentially from 1 to 170 and are designated by an uppercase M where the 
ORF has sequence similarity to an HCMV ORF or by a lowercase m for ORFs not 
conserved (143). 
HCMV life cycle 
As shown in Fig. 2, the HCMV life cycle begins when the virus attaches to the 
cell surface. Initial attachment is accomplished by tethering of viral glycoproteins, gM, 
gN, and gB to heparin sulfate proteoglycans expressed ubiquitiously on the surface of 
cells (13, 30, 83). Tethering is followed by more stable interactions between viral 
glycoproteins and one or more cell surface receptors leading to fusion and internalization 
of the viral capsid and tegument proteins (13, 114). Integrins (43, 74, 192), platelet-
4 
derived growth factor receptor (167), and epidermal growth factor receptor (193) have all 
been implicated as cellular entry receptors with utilization likely dependent on the host 
cell. Post-entry capsids are then transported to the nuclear pores where the viral genome 
is released (114). 
FIG. 2. Life cycle of HCMV. The life cycle begins when the virus attaches to receptors at the cell 
surface (1). Virus fuses with cell membrane (2). Capsid and tegument are released into the cytoplasm (3) 
and then the capsid travels to the nucleus (4). Viral genes are transcribed and translated (5) some of which 
enter the nucleus for capsid formation (not shown). Viral DNA is replicated (6), nucleocapsids are formed 
(7), and bud through the dual membrane of the nucleus (8). Some tegumentation is thought to occur in the 
nucleus (not shown) and cytoplasm (9). Viral glycoproteins are transported to the cell surface (not shown). 
Tegumented capsids acquire a double membrane along with viral glycoproteins from cytoplasmic vesicles 
(10). The viral envelope fuses with the cell membrane (11) and budding results in virions with a single 
membrane (12). 
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Replication of DNA proceeds with three temporal waves of viral gene expression 
termed immediate early, early, and late, where each phase of expression controls 
progression to the next (114, 164). Immediate early gene expression follows entry, is 
independent of expression of viral genes, and occurs via cellular transcription factors and 
viral transcriptional transactivators found in the tegument (114, 164). Generally, 
expression of immediate early genes yields non-structural products that inhibit apoptosis, 
inhibit anti-viral host protein shutofF, modulate expression of MHC class I expression, 
and are transcriptional transactivators required for expression of viral early and late genes 
(23, 114). Expression of many early genes results in products required for replication of 
viral DNA (164). HCMV encodes numerous enzymes and proteins involved in 
transcription and DNA replication, for example, the DNA polymerase and associated 
processivity factor, the single-stranded DNA binding protein, and among others, enzymes 
involved in nucleotide metabolism (114). Late gene expression follows genome 
replication and mainly yields structural proteins including glycoproteins, tegument 
proteins, and proteins required for capsid formation (164). 
Viral DNA replication and capsid formation occur in the nucleus of infected cells. 
Viral capsid proteins and other viral proteins required for capsid formation form some 
interactions in the cytoplasm, but are ultimately transported to the nucleus for final 
procapsid assembly and formation (48). Maturation of procapsids occurs with a series of 
cleavages of the scaffolding elements mediated by a viral protease (48). DNA-containing 
nucleocapsids are formed when the viral terminase recognizes signals on the 
concatameric DNA and interacts with the procapsid to position the DNA for packaging 
(48). Mechanics of packaging are not fully understood, but result in cleavage of the 
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concatameric DNA leading to deposition of single, full-length genome in the 
nucleocapsid (48). 
Mature virions are formed after tegumentation of nucleocapsids and envelopment 
at the cell surface (40). A temporary envelope is formed when nucleocapsids bud from 
the inner nuclear membrane and is shed after budding through the outer nuclear 
membrane. Addition of some tegument proteins may occur during nuclear egress, but 
tegumentation is thought to occur largely in the cytoplasm in distinct compartments (40, 
68, 154, 155). Viral glycoproteins are processed via cellular machinery and are 
transported to the plasma membrane (40). Presently, tegumented capsids are thought to 
acquire a double membrane along with the processed viral glycoproteins from 
cytoplasmic vesicles which then fuse with the plasma membrane during exocytosis 
resulting in release of mature virions with a single envelope (40). 
HCMV pathogenesis and epidemiology 
HCMV is transmitted through urine, saliva, tears, semen, cervical secretions, and 
breast milk (130). As a consequence of primary infection shedding can occur for 
prolonged periods of months to years (130). Naive individuals are thought to contact 
virus at mucosal surfaces in the respiratory tract, upper alimentary tract, or genitourinary 
tract under natural conditions (130). Transmission from mother to baby can occur 
transplacentally, intrapartum, or during breast feeding. Additionally, primary infection 
can be transmitted to naive people in blood products or transplanted tissues (130). After 
acute infection, lifelong latency is established giving rise to periodic reactivations (130, 
159). 
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The virus infects a variety of different cell types including endothelial cells, 
epithelial cells, stromal cells, fibroblasts, hepatocytes, smooth muscle cells, neuronal 
cells, neutrophils, and monocytes/macrophages (71, 117, 160). As a consequence of this 
broad cell tropism disease manifestations are observed in most tissues/organs of the 
immunocompromised host including salivary glands, lung, liver, pancreas, kidney, eye, 
ear, placenta, alimentary tract, heart, ovaries, pituitary, adrenals, thyroid, brain, and skin 
(130). Monocytes of the peripheral blood and their CD34+ progenitors in bone marrow 
are believed to be sites of viral latency (96, 106, 159,181). 
HCMV infection is rather ubiquitous worldwide and prevalence increases with 
age although the age of initial infection and overall prevalence correlates with 
socioeconomic status (130). Generally, higher prevalence and lower age at acquisition of 
infection is observed within developing countries and in groups with lower 
socioeconomic status in developed countries (130). In the United States it is estimated 
that 1.5 per 100 adults (age 12-49) are infected each year in high income classes whereas 
that number increases to 3.5/100 people in low income classes (29). 
Generally, infection of immune competent people is asymptomatic, but can result 
in mononucleosis and symptoms ranging from the more common malaise, headache, 
fatigue, and fever, to the less common lymphadenopathy, pharyngitis, splenomegaly, 
hepatomegaly, and rash (130). 
HCMV infection is the leading viral cause of birth defects and symptomatic 
congenital infections present with multisystem involvement (130). Symptoms such as 
jaundice, hepatitis, hepatosplenomegaly, petechiae, and thrombocytopenia can lead to 
severe disease, but typically clear within a few weeks after birth (130). However, 
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symptomatic infections involving the central nervous system (CNS) can result in 
permanent damage including hearing loss, impaired vision, cerebral palsy, and mental 
retardation (130). Approximately 5% to 10% of congenital infections result in 
symptoms, but 7-25% of asymptomatic infants are prone to CNS sequelae (130). 
Immunocompromised individuals such as bone marrow and solid organ transplant 
patients, chemotherapy patients, and acquired immunodeficiency syndrome (AIDS) 
patients can suffer from minor symptoms such as self-limited fevers to major multisytem 
disease (130). Severity of infection correlates with degree of immunosuppresion (66, 
130). Morbidity of transplant recipients can vary depending on type of transplantation 
and the most common symptoms are fever, leukopenia, malaise, arthralgias, and macular 
rash although more serious disease including pneumonitis, gastrointenstinal ulceration, 
severe hepatic dysfunction, opportunistic fungal infection, and impaired graft function 
can also occur (130). Within one year of transplantation 75% of organ recipients are 
affected by some form of HCMV disease (66). The source of infection is reactivation of 
latent virus either within the recipient or in donor organ, cells, or blood products with the 
latter resulting in more severe disease for seronegative recipients (130). For AIDS 
patients the introduction of highly active antiretroviral therapy has significantly decreased 
HCMV disease by preventing severe immunodeficiency (66). However, symptoms still 
occur with the most common being retinitis with associated vision loss and less common 
CNS diseases including polyradiculopathy and encephalitis (66). 
The murine model of CMV infection and disease 
Due to the strict species specificity of Cytomegaloviruses, numerous animal 
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models have emerged for the study of HCMV pathogenesis. The MCMV model is an 
appropriate model due to the similarities between the two viruses in virion structure, 
genome content, and pathogenesis. In addition to conservation in virion structure and 
morphology, the protein content of the virions is very similar. Recently, proteomic 
approaches were utilized to analyze the viron proteome of both HCMV and MCMV (85, 
176). Except for glycoproteins, the number of structural proteins isolated from the 
virions was strikingly similar including five HCMV capsid proteins compared to four for 
MCMV and fourteen HCMV tegument proteins compared to ten for MCMV (85, 176). 
Furthermore, of the 58 MCMV proteins identified (38 with known function) and the 59 
total proteins isolated from HCMV, 32 of these are homologous (85, 176). 
The genomes also have numerous properties in common. First, the genomes are 
nearly identical in size at approximately 230 kbp and of these 180 kbp are essentially 
collinear with similar gene organization (21, 143). The G + C content is also similar at 
many points across the two genomes (21, 143). Furthermore, 78 ORFs of MCMV are 
generally homologous to HCMV ORFs and the viruses share various conserved gene 
families (21, 143). The viruses share many functional homologs some with little or no 
sequence homology (18) and like HCMV, MCMV displays a temporal wave of gene 
expression (95, 114). 
Importantly, the viruses exhibit similarities in pathogenesis making MCMV an 
appropriate model for HCMV. As with HCMV, infection of adult MCMV-resistant mice 
with virulent virus is usually asymptomatic, acute infection is followed by latency, and 
the virus can be reactivated upon immune suppression of the infected host (18, 95). 
Infection of MCMV-susceptible mouse strains results in morbidity and mortality. 
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Genetic comparisons between resistant and susceptible strains of mice have determined 
that resistance correlates with an ability to control early infection via natural killer (NK) 
cells (18, 95). Similarly, severe HCMV disease is observed in humans with NK cell-
deficiency (95). As with HCMV, MCMV infection in immunocompromised adult mice 
is severe. The viruses exhibit similar cell and organ tropism and, as with HCMV, 
multiple organ damage is observed with severe morbidity and high mortality in MCMV-
infected immunocompromised mice (95). Similar to HCMV congenital infection, 
experimental infection of mouse neonates results in CNS damage and developmental 
abnormalities (95). However, MCMV is not a model for transplacentally acquired 
infection as the murine virus does not cross the placenta. 
Macrophages as determinants of CMV pathogenesis 
Macrophages and their precursors, monocytes, are considered a critical cell type 
for HCMV and MCMV pathogenesis. These cells are involved in all stages of infection 
as they are important in acute infection, as well as in persistence and latency. Contact 
with HCMV-infected bodily fluids results in virus replication in epithelial cells and 
endothelial cells at initial sites of infection which then spreads to the peripheral blood 
(PB) where monocytes become infected (160). HCMV and MCMV encode chemokine 
homologs that attract leukocytes to initial sites of infection and promote a monocyte-
associated viremia (133, 152). This may be a strategy for viral dissemination as 
monocytes are believed to be responsible for viral spread from the PB to host tissues (52, 
162, 174, 203). 
Although monocytes are the prominent cell type infected in the PB and harbor 
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CMV genomes, they are not productively infected (35, 98, 108, 166, 180, 181, 188, 189). 
In some cases viral gene expression has been detected, but is limited to early events and 
virus is not released from cultured monocytes or in the PB of infected individuals (41, 49, 
113, 148, 181, 182). Instead, monocytes and hematopoietic precursor cells have been 
shown to be sites of viral latency (78). Virus can be reactivated in these cells and 
productive infection is related to the degree of differentiation of monocytes into 
macrophages (45, 71, 78, 165, 182). Yurochko and Huang (203) demonstrated that 
HCMV binding to peripheral blood monocytes initiates signal transduction events 
resulting in production of inflammatory cytokines. Further studies showed that even in 
the absence of viral gene expression, HCMV induces differentiation of these cells into 
macrophages which display transendothelial migration and increased cell motility (162, 
163). A model was proposed from these studies suggesting that HCMV induces 
monocyte differentiation to allow spread of infectious virus to host tissues (162). 
Macrophages as deterrents of CMV pathogenesis 
In addition to their role as determinants of CMV pathogenesis, macrophages also 
have a role as mediators of the innate immune response against CMV. For example, 
macrophages are induced by the type n interferon, interferon gamma (IFN-y), to produce 
nitric oxide (156), which can inhibit CMV replication in several human cell lines and in 
infected mice (12, 97, 122, 126). Type I interferons (IFNot/p) produced by macrophages 
and dendritic cells can also limit viral replication (36, 197) and appear to modulate the 
innate and adaptive immune response during MCMV infection (34). Two antiviral 
agents, tumor necrosis factor alpha (TNFa) and virus inhibitory protein, endoplasmic 
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reticulum-associated, interferon-inducible (viperin), produced by macrophages are 
induced by CMV infection (25, 57, 198, 206). Both proteins inhibit viral replication and 
have been shown to block late gene expression (25, 65). Certain antiviral effects appear 
to be macrophage-specific. For example, Presti et al. (140) demonstrated that IFN-y 
inhibits the growth of MCMV more efficiently in macrophages than fibroblasts. Genes 
regulated in response to IFN-y were different in macrophages and the antiviral effects 
were independent of known mechanisms (140). Thus, while differentiation of monocytes 
into macrophages favors virus production, activation of macrophages by inflammatory 
mediators leads to an antiviral state (57). 
CMV has evolved to counteract many of these macrophage-induced antiviral 
effects. For example, HCMV inhibits gene expression of IFNa-induced antiviral 
effectors by blocking signal transduction (112). In HCMV infected cells viperin 
distribution is dramatically altered, perhaps as a means for the virus to evade the harmful 
effects of the protein (25). MCMV disrupts TNFa autocrine responses in macrophages 
by reducing levels of TNF receptor on the cell surface (138). Given their importance in 
infection it is not surprising that CMV has developed numerous strategies for avoidance 
of immune recognition in macrophages. For example, HCMV and MCMV inhibit 
antigen presentation to CD4+ T lymphocytes by down-regulating major 
histocompatibility complex (MHC) class II molecules (63, 124, 145). Specific MCMV 
products also prevent expression of MHC class I molecules on the surface of 
macrophages, thus preventing antigen presentation to cytotoxic T lymphocytes (100). In 
addition, HCMV infection of activated macrophages results in up-regulation of HLA-G, 
which likely provides protection of the infected cell from immune killing (127). 
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Ml40 and Ml 41 are determinants of macrophage tropism 
Presently, despite the crucial role of monocytes/macrophages in CMV immunity 
and pathogenesis, only a limited number of MCMV genes have been identified that are 
important for optimal growth in these cells (57). We have demonstrated the importance 
of the Ml 40 and Ml 41 genes in macrophage tropism. Compared to wild type (WT) 
MCMV, a mutant virus (RV10) disrupted of M140, M141, and adjacent gene M139, 
shows nearly 3 logio lower growth in the differentiated macrophage cell line, IC-21, but 
not in fibroblast cells (62). A growth defect of over 2 logio was also found at peak titers 
in primary, differentiated macrophages obtained by peritoneal lavage (62). Importantly, 
we found a similar growth defect in the macrophage-dense spleens of infected BALB/c 
mice. Although WT virus replicated to as high as 104 plaque forming units (PFU)/ml on 
day 3 postinfection, RV10 displayed little to no growth in this organ (62). We also tested 
the virulence of RV10 in SCID mice which lack functional T and B lymphocytes. 
Although virulence of tissue culture-passaged virus is attenuated in BALB/c mice, SCID 
mice are exquisitely sensitive. We found that infection with 104 PFU of WT virus was 
100% lethal in these mice by 28 days postinfection, but mice infected with RV10 
survived at least 90 days postinfection (62). 
Our current model predicts that replication in macrophages is an important factor 
in MCMV virulence and therefore, the virus has evolved strategies to ensure growth in 
this cell type. We further characterized the growth of viruses individually disrupted of 
expression of the M139 (RVA139), M140 (RVA140) and M141 (RVA141) genes. 
Although RVA139 had no growth defect in IC-21 macrophages or the spleens of BALB/c 
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mice (61), our collaborators have shown that a transposon insertion mutant of Ml 39 is 
defective for growth in IC-21 macrophages (105). We found that RVA140 displayed a 
nearly identical growth defect to that of RV10 in IC-21 macrophages and in the spleens 
of BALB/c mice (61). However, RVA141 displayed an intermediate phenotype, both in 
vitro and in vivo. While RV10 and RVA140 have a nearly 3 logio lower growth than WT 
virus in IC-21 macrophages, RVA141 replication is at most 2 logio lower than WT (61). 
Likewise, replication of RV10 and RVA140 in the spleen is nearly undetectable, but 
RVA141 replicated as high as 103 PFU/ml in this tissue (61). Thus, pM140 and pM141 
are determinants of macrophage tropism and given the importance of 
monocytes/macrophages in viral spread and dissemination, are important for viral 
pathogenesis. 
Characterization of pM140 and pM141 
We previously characterized expression of Ml 40 and Ml 41 at the level of mRNA 
and protein. The transcripts of MHO and M141 are expressed with early kinetics, and 
are 3' coterminal with each other and with transcripts of an adjacent gene, Ml 39 (59). 
The protein products of the M140 and M141 genes are expressed at early and late times 
with similar kinetics and correspond to proteins of 56 kDa and 52 kDa, respectively (61). 
Steady-state levels of the proteins increase over the course of infection, beginning at three 
hours post-infection in fibroblasts and at six hours post-infection in IC-21 macrophages 
(61). Both proteins are members of the US22 gene family (see below) and contain all 
four motifs characteristic of the family and pM140 also contains an acidic domain (Fig. 
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Motif I: Consensus - OXOXXPXXW 
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pM141 - 54 IPLGFPQDW 
Motif II: Consensus - OOCCX-XLXXOG 
pM140 - 86 IVCCDEPLTWG 
pM141 - 82 LLCCEEALIPLG 
Motif III: 
pM140 - 109 EDftGAALCLGAWTRVFVYEIQEDflMILVAPDLDKIARFGLLHCETLYRR 
pM141 - 111 GYGVSLVLSGEYGRVYVYTASDDTLHLVARNLEELGRFGISRRSFAYKE 
Motif IV: 
pM140 - 2 6 1 FSIHHLLVIDTFGAIYTLDMQREKFYRVADGITMLLRAGMAK 
pM141 - 284 FRADHVIVADKFGAVYSLIiVYSRAGLTRRVADSVAEFFQMGMLK 
B. 
pM140 Acidic Domain: 386 TNEEEDWTDTNEWEQEDDDN 
c. 
pM141 Putative MLS: 317 KRVFSSSFEFRQRERRK 
D. 
pM141 PEST domain: 360 RFDSPTDDEDYVPADCMAE 
FIG. 3. Known or predicted motifs in the amino acid sequence of pM140 and pM141. Numbers 
represent amino acids corresponding to the position of the motifs in the protein sequence. A. Diagram of 
full length pM140 and pM141 showing the location of protein domains (top). The location of TJS22 motifs 
is represented in each protein as open boxes. In pM140 the location of an acidic domain is represented by a 
black box. In pM141 the location of a putative NLS (nuclear localization signal) is represented by a 
hatched box and a PEST motif is represented by a white box. M140 and M141 belong to the US22 gene 
family which can contain up to four conserved motifs with unknown function. Both proteins contain all 
four motifs as shown. The consensus sequence of Motifs I and II are shown. Motifs HI and IV are less 
well defined, but are characterized by stretches of nonpolar residues. Hydrophobic residues are denoted by 
O, any amino acid by X, and nonpolar residues are underlined. B. M140 contains an acidic domain. 
Acidic residues are underlined. C. M14 lis predicted to contain a NLS. Basic residues are underlined. D. 
M141 is predicted to contain a PEST motif rich in proline (P), glutamic acid (E), serine (S), threonine (T). 
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The proteins exist in at least two stable complexes in infected macrophages and 
fibroblasts as determined by immunoprecipitation analysis using high stringency salt and 
detergent washes (82). One complex is composed of pM140, pM141, pM139, and an 
unidentified protein of approximately 98 kDa (82). Sucrose gradient purification of these 
proteins predicts that the four proteins exist as one or more large complexes, estimated to 
be as large as 669 kDa (82). A second complex found in infected cells is composed of 
pM140 and pM141 formed in the absence of pM139 (82). This complex is predicted to 
be 158 kDa and thus may be composed of, for example, two pM140 molecules and one 
pM141 molecule (82). Although the stoichiometry of the pM140 and pM141 complex 
has not been determined, this predicted ratio is supported by the relative intensities of the 
co-immunoprecipitated pM140 and pM141 bands (82). Alternatively, a third unidentified 
protein of approximately 50 kDa could be a component of this complex. We have also 
demonstrated complex formation between pM140 and pM141 expressed from 
transiently-transfected cells and from in vitro translation (82). Thus, pM140 and pM141 
complexing may take on various forms and may include other viral or cellular proteins. 
In addition, the composition of the complexes may vary with cell type. 
The MHO and M141 proteins have differential patterns of localization when 
expressed individually or together. We have demonstrated, using cell fractionation 
techniques, that both proteins can be isolated from the nucleus and the cytoplasm of 
infected fibroblasts and IC-21 macrophages (61). The MHO protein is found almost 
exclusively in the nucleus of transiently-transfected fibroblasts or macrophages while 
pMHl is distributed diffusely throughout the cytoplasm and to a lesser extent, the 
nucleus (82). Interestingly, the only localization signal predicted by bioinformatics 
analysis is a putative nuclear localization signal in pM141 (Fig. 3C). Confocal 
microscopy analysis of fibroblasts and IC-21 macrophages transiently expressing both 
proteins demonstrates that the proteins predominantly co-localize to a perinuclear region 
(82). The proteins co-localize with cw-Golgi markers, but not with a marker directed 
against the *ra«s-Golgi compartment (82). Further analysis of the localization of pM140 
revealed that this perinuclear region is adjacent to enlarged microtubule organizing 
centers observed specifically in infected macrophages and not in fibroblasts (60). These 
centers were found to have characteristics of aggresomes which are concentrated sites of 
proteasomes, mitochondria, and chaperone proteins for the degradation of aggregated 
proteins that have traveled to the microtubule organizing center (31, 196). If the 
aggresomes are unable to degrade the protein aggregates, degradation may occur through 
autophagy(31, 196). 
Further characterization of RVA140 demonstrates an indirect function of pM140 
in stabilizing viral capsids. The number of viral particles is reduced in RVA140-infected 
cells and steady-state levels of two virion proteins, the major capsid protein (MCP) and a 
tegument protein, M25, were reduced specifically in RVA140-infected macrophages and 
not fibroblasts (60). Although we did not determine the half-life of M25, the half-life of 
the MCP was found to be 9 hours in WT-infected cells compared to 6 hours in RVA140-
infected cells (60). The localization of pM140 adjacent to aggresome-like structures 
formed in macrophages, the reduction in levels of virion proteins, and the reduction in 
viral capsids suggests that capsid stability is affected by pM140 indirectly through the 
more general role of regulating viral protein stability in macrophage cells. 
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Although the functionality of the domain has not been investigated, pM141 
contains a PEST domain and these domains are found on rapidly degraded proteins (Fig. 
3D (144, 149)). We have observed a reduction in the steady-state levels of pM141 and 
the half-life of the protein is reduced from 2 hours in WT-infected cells to 1 hour in 
RVA140-infected cells (61). However, this effect of pM140 is observed in both 
macrophages and fibroblasts and thus, may reflect regulation of pM141 by pM140 in all 
cell types. 
US22 Gene Family 
MHO and M141 are members of the US22 gene family found in all beta-
herpesviruses (59, 143). Members of this gene family contain up to four conserved 
motifs with unknown function (94, 120). US22 motifs I and II have consensus sequences 
while motifs HI and IV are defined by stretches of nonpolar amino acids (94). The Ml40 
and M141 proteins contain all four US22 motifs as shown in Fig. 3 A. 
M140 and M141 are homologs of HCMV genes US23 and US24, respectively, 
neither of which are essential genes (21, 143, 201). Unlike their murine counterparts, 
US23 and US24 are required for efficient viral growth in fibroblasts and have been 
isolated from virion particles (37, 201). Presently, US23 has not been studied in greater 
detail. However, US24-deficient mutants have a replication defect in fibroblasts after 
viral DNA travels to the nucleus, but prior to expression of immediate-early genes (44). 
Thus, although US23 and US24 are homologous to M140 and M141 based on similarities 
in sequence, there is no apparent functional homology between these human and mouse 
US22 genes. 
In addition to US23 and US24, HCMV has 10 other US22 family member genes 
including UL23, UL24, UL28, UL29, UL36, UL43, IRS1, TRS1, US22, and US26 (21). 
Of these only UL28, UL29, TRS1, US23, US24, and US26 have been shown to enhance 
replication of the virus in fibroblasts while the remaining six are dispensable for growth 
in this cell type (201). Of the genes where functional mechanisms have been 
investigated, the UL36 protein has been shown to inhibit Fas-mediated apoptosis by 
preventing activation of caspase-8 (161), the TRS1 protein is required for efficient 
assembly of DNA-containing capsids (1), the IRS1 and TRS1 proteins are transcriptional 
transactivators of numerous viral genes (86, 151, 171), and the IRS1 and TRS1 proteins 
inhibit anti-viral host protein shutoff likely by preventing activation of protein kinase R 
(23, 55). Restriction of primary HCMV replication to fibroblasts and a very limited 
number of other cell types in vitro has hindered studies on the role of these US22 family 
genes in cell type-specific replication. 
Ten additional US22 genes are also found in MCMV including M23, M24, 
m25.1, m25.2, M36, M43, M128, M139, ml42, and ml43 (143). Of these, only ml42 
and ml43 are essential genes and function similar to IRS1/TRS1 in blocking activation of 
protein kinase R (16, 22, 24, 58, 105, 185). Interestingly, ml42 and ml43 also form a 
complex; in fact, complexing is required to bind double-stranded RNA and PKR (22). 
M136, a sequence and positional homolog to HCMV UL36, has similarly been found to 
inhibit Fas-mediated apoptosis by binding to caspase-8 (105). Comprehensive mutational 
analysis of MCMV US22 genes demonstrated the requirement of M43 for optimal viral 




The MHO and M141 proteins form a complex in infected cells (82). We 
hypothesized that the proteins function as a complex to optimize replication in 
macrophages. Proper functioning of many proteins requires that they interact with 
regulatory proteins or form complexes that confer functional properties. These 
protein/protein interactions are involved in every aspect of cell biology and disruption of 
protein complexing may lead to disease (131). Furthermore, viruses have numerous ways 
to co-opt cellular protein/protein interactions for their benefit or to disrupt these 
interactions when they are inhibitory to viral pathogenesis (114). Proteins rarely function 
as isolated entities and may either function in complex with one or a small number of 
other proteins or, in some cases, as large multi-protein complexes (3, 87, 115). In fact, 
complexes often or more proteins mediate most of the major cellular processes (3). 
Multi-protein complexes function in replication, transcription, splicing, translation, and 
protein degradation (3, 205). 
In addition to large protein machines, myriad regulatory interactions occur 
between protein pairs that are strictly required for protein function and may be transient 
in nature or more stable (205). Transient protein/protein interactions are required for 
signaling cascades, post-translational modifications, enzyme reactions, and translocation 
of proteins to distinct subcellular locations (87, 115, 131, 205). More stable interactions 
are required to regulate temporally-controlled proteins such as transcription factors (87). 
Complexing of transcription factors with regulatory proteins inhibits function of the 
transcription factor until the expression of the target genes is required (118). 
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Interactome mapping has become possible with the advent of in silico methods 
and high-throughput proteomic techniques. Experiments involving the interactome have 
demonstrated that most proteins only interact with a few other proteins while a much 
smaller proportion of proteins can interact with a large number of partners (56). Surface 
areas of proteins are limiting and some interaction domains are specific to bind to single 
proteins (87). In other cases where proteins are able to bind to numerous partners, the 
binding site of these proteins contains critical amino acid residues that make conserved 
interactions with multiple partners (87). 
Protein/protein interactions occur through interaction domains in the proteins and 
these domains may be conformation-dependent or -independent (87). Complex 
formation between proteins is mediated by shape, chemical complementarity, and 
flexibility of proteins and occurs at the surface of the proteins through weak, noncovalent 
interactions (87). Complexing among proteins may be constitutive, as in the case of the 
proteasome, or may be transient and induced, as is the case with cell signaling cascades. 
The amino acids residues located at the protein interface vary with the type of interaction 
(87, 131, 132). This is likely due to the strength of interaction as constitutive complexing 
generally is formed from hydrophobic interactions and transient interactions are more 
reliant on salt bridges and hydrogen bonds (87). 
An excellent example of the myriad protein/protein interactions that are required 
to regulate a single protein is that of the transcription factor, nuclear factor-KB (NF-KB). 
The first level of regulation relates to function and is within the protein molecule. NF-KB 
is a dimeric molecule composed of members of the Rel family of proteins (103). Since 
each subunit makes contacts with DNA, different combinations of complexed subunits 
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have an ability to regulate transcription of different genes (103). Furthermore, different 
dimers can alternately activate or repress transcription of genes (103). 
Another layer of complexity is that NF-KB activation of target genes is not 
constitutive and thus must be regulated. This regulation occurs by complexing between 
NF-KB and another protein, IKBCI. Despite the fact that NF-KB has a NLS that is 
required for entry into the nucleus the protein remains localized to cytoplasm in most cell 
types due to protein/protein interactions with IKBOC that mask the NLS (103). Yet another 
level of complexity is that IicBa not in complex is a rapidly degraded protein (104). NF-
KB complexing masks the degradation signal of IKBO. preventing rapid degradation (104). 
Activation of NF-KB requires numerous transient protein/protein interactions. 
Activation begins at the cell surface where complexing between inflammatory cytokines 
or pattern recognition molecules and their respective receptors leads to several possible 
signaling cascades. These cascades encompass numerous transient interactions between 
proteins whereby upstream effectors are activated and phosphorylate downstream 
effectors ultimately leading to phosphorylation of IKBCC (103). Phosphorylation of the 
protein allows it to be recognized by a ubiquitin ligase that adds ubiquitin moieties 
through transient interactions causing degradation of the protein, release of NF-KB, 
unmasking of the NLS, and allowing NF-KB to interact with transport proteins that carry 
it into the nucleus (84, 103, 183). Once in the nucleus NF-KB regulates expression of 
numerous genes involved in immune responses (103). 
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Nucleocytoplasmic transport 
The MHO protein is localized predominantly in the nucleus while pM141 is 
localized diffusely throughout the cytoplasm and, to a lesser extent, the nucleus (82). 
However, co-expression alters the localization of either protein and they are found co-
localized in a perinuclear region adjacent to aggresomes (82). Transport of most proteins 
from the cytoplasm to the nucleus is regulated and occurs through large nuclear pore 
complexes (Fig. 4 A), up to 125 MDa in size, embedded in the dual membrane of the 
nuclear envelope (33, 146). These complexes are composed of 500-1000 total proteins 
called nucleoporins that are mostly soluble (32, 33). The nucleoporins form a 
symmetrical scaffold embedded in the nuclear envelope that surrounds a channel 
bounded by a cytoplasmic and nuclear ring. Each ring has filaments attached with the 
cytoplasmic side having loose ends and the nuclear filaments forming a distal ring called 
the nuclear basket. Ions and some proteins up to approximately 60 kDa in size can 
traverse the nuclear pore by passive diffusion (102, 137, 168, 190). However, larger 
proteins must be actively transported into the nucleus. In addition, transport of many 
small proteins is also regulated. Presently, the nature of the permeability barrier is still 
under debate, but the channel is lined with the nucleoporins that contain multiple repeats 
of phenylalanine (F) and glycine (G), the so-called FG-nups, necessary for directed 
transport of proteins (7-10, 147, 175, 183). 
Nuclear import or export of proteins (Fig. 4B) is typically controlled by specific 
signals, nuclear localization signals (NLSs) or nuclear export signals (NESs), 
respectively, found in the primary sequence of the protein or formed from secondary or 
tertiary structural elements (183). Soluble transport receptors bind the signal-containing 
A. 
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FIG. 4. Structure ofthe nuclear pore and nucleocytoplasmic shuttling. A. Representation of the nuclear 
pore with arrows pointing to the location ofthe cytoplasmic and nuclear rings, nuclear basket, cytoplasmic 
filaments, and nuclear membrane. B. Schematic representation of nuclear import (left) and nuclear export 
(right). The first step of nuclear import occurs when an import receptor binds to a NLS-containing target 
protein (1). The target protein/receptor complex enters the nucleus (2) by interacting with nucleoporins of 
the nuclear pore (not shown). In the nucleus, binding of RanGTP to the receptor causes release ofthe 
target protein (3) and the RanGTP/receptor complex is recycled back to the cytoplasm (not shown). The 
first step of nuclear export is complex formation of a RanGTP-bound export receptor with a NES-
containing target protein (1). The complex crosses the nuclear pore (2) via interactions with the receptor 
and nucleoporins (not shown). Upon entering the cytoplasm, GTP is hydrolyzed causing the complex to 
dissociate (3) after which the receptor is recycled back to the nucleus (not shown). 
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cargo proteins and are thought to interact with the FG repeats of the FG-nups through 
multiple, low-affinity binding reactions during nuclear translocation (183). In other cases 
adaptor molecules bind to the signal sequences and are themselves bound by the transport 
receptors (199). Directionality of transport is controlled by the gradient of small guanine 
triphosphatase (GTPase), Ran, and its associated factors (75, 199, 200). Export receptors 
bind cargo in complex with RanGTP in the nucleus where the RanGTP levels are highest. 
Cargo is released in the cytoplasm upon hydrolysis of RanGTP after which the receptor 
and RanGDP are recycled back to the nucleus. On the other hand, import receptors bind 
cytoplasmic cargo in the absence of RanGTP and release cargo upon binding to RanGTP 
in the nucleus. The RanGTP/import receptor complex is recycled back to the cytoplasm 
where hydrolysis of RanGTP results in release of the import receptor for re-use. 
The first NLS identified, PKKKRKV (single letter amino acid code), was that of 
the simian virus 40 (SV40) large T antigen (80). This and other so-called classical NLSs, 
or basic type NLSs, are monopartite or bipartite clusters of basic amino acids (200). 
Different classes of NLS have been identified with no known homology to the basic type 
NLS and are imported through distinct transport receptors, but import of basic NLS-
containing proteins has been more extensively studied (172, 200). Nuclear import of 
these proteins requires a nuclear pore targeting complex composed of importin a and 
importin P (73, 141). The NLS is recognized and bound by the importin a adaptor 
protein (51). The importin P receptor transports the NLS-containing cargo 
protein/importin a complex into the nucleus (50, 72). 
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Presently, the most well characterized NESs are the leucine-rich NESs which are 
rich in hydrophobic amino acids and require leucine residues for function (200). The 
leucine-rich NESs are recognized and bound by the CRM1 receptor and are transported 
to the cytoplasm by CRM1 in complex with RanGTP (46, 47, 170). 
Proteasome-mediated protein degradation 
In the absence of pM140, steady-state levels of pM141 are reduced and pM141 is 
degraded at a faster rate (61). The most common mechanism of protein degradation is 
via the proteasome which is a 2.5 MDa multisubunit complex with three proteolytic 
activities including chymotrypsin-like, trypsin-like, and caspase-like activities (77, 92, 
128). Proteasomes are fairly evenly distributed throughout the nucleus and cytoplasm, 
but are concentrated at distinct subcellular sites (135). For example, the microtubule 
organizing center is enriched in proteasomes and serves as a major site for the 
degradation of aggregated proteins (196). 
The proteolytic core or 20S proteasome (Fig. 5 A) is cylindrical in shape and 
consists of four stacked rings (77, 92). Each ring is composed of seven different, related 
subunits with the two identical outer rings containing a subunits (ocl - a7) and the two 
identical inner rings composed of 0 subunits (01 - 07). The catalytic sites are contained 
in the inner subunits while the outer subunits interact with the 19S regulatory complex 
and a variety of other regulatory complexes. Each 19S regulatory complex is composed 
of at least 18 different subunits arranged as a base and lid (77). The lid contains a ring of 
ATPases and directly interacts with the 20S core particle. The 20S proteasome along 
with two 19S complexes composes the 26S proteasome (128). 
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FIG. 5. Structure of the 20S constitutive proteasome (A) and immunoproteasome (B). The constitutive 
20S proteasome (A) consists of four stacked rings containing 14 different subunits (represented as circles). 
The outer rings are composed of seven different a subunits (al-a7) and the inner rings are composed of 
seven different P subunits ((31-J37) that contain the proteolytic machinery (not shown). Upon IFN-y 
stimulation, biogenesis of the immunoproteasome (B) occurs with incorporation of (31i, p2i, and |35i in 
place of the pi, P2, and P5 subunits. 
Both 26S and 20S proteasomes can be isolated from mammalian cells (77, 92, 
128). Access to the catalytic sites of the 20S proteasome is gated by the a subunits 
thereby limiting access to the closed chamber (53, 54, 101, 194). Association of the 19S 
regulatory complex or one of two additional regulatory complexes, proteasome activator 
(PA) 28 and 200, results in opening of the chamber and thus, the regulatory complexes 
control translocation into the chamber (77, 93, 195). In addition, the regulatory subunit 
recognizes the targeted proteins and, through the action of the ATPases, is responsible for 
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their unfolding and transfer into the catalytic chamber (77, 93, 195). Thus, it was long 
believed that only the 26S proteasome was capable of proteolysis. However, the core 
20S proteasome has been implicated in the degradation of numerous proteins (4, 128). 
The 20S core contains six active sites with proteolytic activity categorized by 
similarities in substrate specificity rather than by catalytic mechanism (92). Cleavage by 
the two chymotrypsin-like or two trypsin-like sites occurs preferentially after 
hydrophobic or basic residues, respectively. The two remaining sites, once referred to as 
peptidyl glutamyl peptide hydrolase sites, cleave preferentially after acidic amino acids 
and are currently referred to as post-acidic or caspase-like sites. Degradation of proteins 
is processive generating peptides between three to twenty-two residues long (2, 91, 123). 
In addition to the 20S proteasome described above formed from subunits that are 
constitutively expressed, a so-called immunoproteasome (Fig. 5B) can also be formed 
from IFN-y-inducible subunits in response to viral infection (177). In the 
immunoproteasome each of the three catalytic subunits in both of the P rings is replaced 
by the IFN-y-inducible catalytic subunits, pii, P2i, and (35i, during biogenesis of new 
proteasomes (177). Furthermore, the rate of biogenesis of immunoproteasomes is 
enhanced compared to that of the constitutive proteasomes (177). In addition to the 
formation of immunoproteasomes, IFN-y upregulates expression of the two subunits that 
form the PA28 regulatory complex (177). Ultimately, these IFN-y-induced changes in 
the proteasome serve as an antiviral response, leading to altered substrate cleavage, 
enhanced generation of specific peptides, and increased variability in antigenic peptides 
that can be displayed for immune recognition of infected cells (14, 177). The 
cyotmegaloviruses have developed mechanisms to counteract this antiviral response. 
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Although MCMV induces immunoproteasome formation in vivo, this induction is 
blocked in IFN-y-induced mouse embryonic fibroblasts in culture (88). HCMV also 
inhibits immunoproteasome formation in cultured cells exposed to IFN-y, including 
fibroblasts and endothelial cells (88, 111). These effects are most likely due to the ability 
of CMV to interfere with IFN-y signal transduction (110, 111, 207). 
A wide variety of reversible and irreversible proteasome inhibitors have been 
identified and are currently being used as tools of cellular and molecular biology (92). 
Many of these are peptide-based compounds attached to a pharmacophore which 
occupies the catalytic site of the protease while the short peptide associates with the 
substrate binding pocket (92). Most of the natural and synthetic compounds inhibit the 
chymotrypsin-like activity of the proteasome because these compounds are more cell 
permeable than inhibitors of the other two proteolytic activities (92). For example, 
MG132 is an irreversible, peptide aldehyde inhibitor of the proteasome which can also 
inhibit cellular calpains and cathepsins at a 10-fold higher concentration to that required 
to inhibit the proteasome (92). Epoxomicin is an example of a peptide epoxyketone 
inhibitor that is irreversible, but is a more specific inhibitor with no known intracellular 
targets (92). Additional classes of peptide inhibitors exist including peptide boronates 
and peptide vinyl sulfones as well as the non-peptide inhibitors, lactacystin and P-lactone. 
Thus, various inhibitors are available to study the role of proteasomes in degradation of 
proteins of interest. 
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Routes to the proteasome 
The majority of proteins currently studied are targeted to the proteasome by 
covalent attachment of polyubiquitin chains (92). Protein ubiquitination occurs by the 
action of two or three enzymes (Fig. 6) (77). First, the El ubiquitin activating enzyme 
activates ubiquitin by the formation of a high energy thioester bond. The activated 
ubiquitin is then transferred to a thiol group of an ubiquitin-conjugating enzyme (E2) 
which, in some cases, can directly transfer the ubiquitin moiety to protein targets. 
However, most protein targets receive ubiquitin from an E3 ubiquitin ligase enzyme 
which acts by either facilitating the transfer of ubiquitin from E2 or by direct transfer 
after binding to the ubiquitin molecule (77). 
Ubiquitin, a small amino acid of 76 residues, is most commonly added to internal 
lysine residues of target proteins via an isopeptide bond between the e-amino group of the 
protein substrate and the C-terminal carboxy group of ubiquitin, but cysteine, serine, and 
threonine linkages have also been observed (17, 77, 179, 191). Multiple additions of the 
ubiquitin moiety result in the formation of polyubiquitin chains with additions to lysine 
48 of ubiquitin being the most common and most commonly associated with proteasomal 
degradation of the tagged protein (77). However, ubiquitin contains 7 internal lysine 
residues and polyubiquitination of other lysine residues as well as monoubiquitination of 
some proteasomal substrates have also been demonstrated to target proteins for 
proteasomal degradation (6, 15, 67, 90). Furthermore, the density of ubiquitin on protein 
substrates is proposed to be as important as the type of ubiquitin linkage or the formation 
of long polyubiquitin chains (77, 90). Nonetheless, for proteins degraded in this 
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pathway, addition of the required ubiquitin moieties targets proteins to the proteasomes 
where the lid of the regulatory complex is thought to recognize the ubiquitinated 
molecules and initiate processing into the proteasome (77). During processing the 
protein substrates are de-ubiquitinated by deubiquitinases and ubiquitin is recycled (77). 
FIG. 6. The ubiquitin-proteasome system of protein degradation. Addition of ubiquitin (Ub) to a target 
protein occurs via the action of three enzymes. First a high energy bond is formed between the El 
activating enzyme (El) and ubiquitin and requires hydrolysis of adenosine triphosphate (ATP) to adenosine 
diphosphate (ADP). In the second step, a bond is formed between the E2 ubiquitin-conjugating enzyme 
(E2) and ubiquitin and in some cases E2 can directly transfer the ubiquitin molecule to the target protein 
(not shown). In the final step an E3 ubiquitin ligase (E3) recognizes the target protein (represented by the 
black line) and facilitates transfer of the ubiquitin molecule. Multiple ubiquitin moieties can be added by 
the successive action of El, E2, and E3 and the ubiquitin moieties are recognized by the regulatory 
complex that is associated with the 20S core proteasome. In reactions requiring ATP, the regulatory 
complex causes protein unfolding and transfer into the catalytic core (not shown) after which the target 
protein is degraded to smaller peptides and the ubiquitin molecules are hydrolyzed for recycling. 
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Proteasomal degradation of proteins can also occur independent of ubiquitin. 
Presently, the mechanisms for this type of degradation are incompletely understood and 
relatively few proteins have been identified that undergo ubiquitin-independent 
degradation. Asher, Reuven, and Shaul (4) proposed a model for ubiquitin-independent 
degradation involving the 20S proteasomes and degradation "by default". Given that 
unstructured regions are common in proteins degraded by the 20S proteasome in an 
ubiquitin-independent fashion, the model predicts that these proteins are inherently 
unstable and will be degraded in a passive process "by default" (4). In fact, some 
proteins with unstructured regions are degraded by the 20S proteasome by affecting 
structure of the cylinder and causing opening of the orifice without the need of regulatory 
complexes (77, 128). 
Nevertheless, both the 20S and 26S proteasomes have been shown to be involved 
in ubiquitin-independent degradation (4, 77, 128). In fact, single proteins can exhibit 
complex degradation involving both forms of the proteasome. For example, ornithine 
decarboxylase (ODC), an enzyme in the polyamine synthesis pathway, is active as a 
homodimer, but the association between dimers is weak and monomers are subject to 
ubiquitin-independent degradation by the 20S proteasome (4, 77). However, when 
polyamine levels are high the antizyme-1 protein is induced, which complexes with the 
ODC, disrupts the homodimer, and directs ubiquitin-independent degradation of ODC 
monomers via the 26S proteasome (4, 77). Notably, despite the fact that ODC appears to 
be an inherently unstable protein due to 20S degradation, accelerated turnover occurs 
upon antizyme-mediated 26S degradation (4, 77). 
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Individual proteins can exhibit degradation by ubiquitin-dependent and -
independent means. For example, ubiquitin-dependent degradation of the tumor 
suppressor protein, p53, has been extensively studied. The E3 ubiquitin ligase, Mdm2, 
binds to p53 and ubiquitinates the protein thereby targeting it for 26S proteasomal 
degradation (5). Several other ubiquitin ligases target p53 for degradation by 
ubiquitination (5). However, p53 is also subject to degradation via the 20S proteasome 
independent of interactions with ubiquitin ligases and may represent ubiquitin-
independent degradation "by default" (4, 5). 
In addition to the growing number of cellular proteins that are degraded by 
ubiquitin-independent pathways, numerous viral proteins also appear to be degraded in 
this fashion (89, 109, 178, 187, 202). For example, MCMV IE pp89 protein is degraded 
by the 20S proteasome independent of ubiquitination (187). In other cases viruses target 
key antiviral cellular proteins for degradation using ubiquitin-independent pathways (20, 
70, 81, 134). For instance, the HCMV pp71 tegument protein can target several cellular 
proteins for ubiquitin-independent degradation (70, 81). Targets include Daxx which has 
the capacity to repress viral gene expression as well as members of the retinoblastoma 
family of tumor suppressors which regulate cell cycle (70, 81). 
Various signals have emerged that target proteins for degradation. For example, 
the PEST domain is observed in the primary sequence of numerous short-lived proteins 
(144, 149). Although there is no consensus sequence the domains are enriched in proline, 
serine, glutamic acid, threonine, and, to a lesser extent, aspartic acid (144, 149). The 
domains are frequently flanked by positively charged amino acids, are uninterrupted by 
positively charged residues, are highly variable in length, and can be found anywhere in 
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the protein sequence (144). The domains serve as either constitutive or conditional 
degradation signals and numerous studies have demonstrated that removal of the motif 
results in increased protein stability while transfer to stable proteins confers instability 
(144). PEST motifs commonly target proteins for degradation by the ubiquitin-
proteasome system (11, 144). However, the motifs also target proteins for degradation by 
proteasome-independent mechanisms and for ubiquitin-independent proteasomal 
degradation (11, 144). For example, IKBOI exists in two forms; as a free molecule and in 
complex with NFKB (104, 157). Unbound IKBO. is degraded by the proteasome in an 
ubiquitin-independent manner that requires the PEST domain located within the C 
terminus of the protein (104). Complexing masks the PEST domain and prevents 




The overall objective of this project was to characterize regulation of pM141 by 
pM140, at the molecular level. The MHO and M141 proteins structurally and 
functionally interact to optimize replication of MCMV in macrophages (61, 62, 105), a 
critical cell type for pathogenesis that supports productive and latent infection (64, 136). 
Structural interaction is evident by formation of a stable pM140/pM141 complex that 
localizes to a perinuclear region proximal to the microtubule organizing center (60, 82). 
Functional interactions are evident in that pM140 stabilizes pM141, increasing its half-
life two-fold (61). Furthermore, co-expression of the proteins results in redistribution of 
pM140 from a diffuse nuclear pattern and pM141 from a diffuse localization in the 
cytoplasm and, to a lesser extent, the nucleus to the perinuclear locale (82). Thus, the 
importance of this project is in understanding to what extent the proteins cooperate to 
function in macrophage tropism and how the proteins are regulated. An understanding of 
how CMV proteins are regulated is fundamental to developing anti-viral therapies that 
are effective, specific, and non-toxic to the host. 
The specific aims of the project were: 
1) To map the interaction domains of pM140 and pM141. Mapping the 
interaction domains within pM140 and pM141 is a prerequisite to generating interaction-
defective alleles within MCMV to assess the role of complex formation in the 
pathogenesis of the virus. Towards this goal, plasmid constructs were generated to 
express N- or C-terminal truncation mutants of pM140 or pM141. Each truncation 
mutant or full-length protein was radiolabeled in in vitro translation reactions. In some 
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cases the mutant proteins were co-expressed with the full-length binding partner and then 
immunoprecipitations were performed to assess which mutant retained an ability to form 
a complex. In other cases the mutant protein was mixed with the full-length binding 
partner expressed as a glutathione S transferase (GST) fusion protein after which GST 
pulldown assays were performed to assess complexing. 
2) To map the localization domain(s) of pM141. It is possible that in addition to 
complexing, proper localization of pM140 and pM141 is important for the function of 
these US22 proteins. The Ml 41 protein is found localized diffusely throughout the 
cytoplasm and, to a lesser extent, the nucleus when expressed individually (82). 
Interestingly, when pM140 and pM141 are co-expressed, pM141 is relocalized to a 
perinuclear region and exhibits a punctate staining pattern (82). Mapping the 
localization domain within pM141 was therefore undertaken as in Aim 1. Truncation 
mutants or full-length pM141 were expressed transiently in NIH3T3 fibroblast cells after 
which the cells were fluorescently stained to detect pM141 or distinct subcellular 
compartments. Localization of each mutant protein was examined by confocal 
microscopy and compared to the localization of the full-length protein. 
3) To determine the method of pM141 degradation and assess the contribution of 
pM140 in protecting pM141 from degradation. It is possible that appropriate levels of 
pM141 are required for proper protein function of pM141, pM140, or both proteins. 
Thus, we sought to determine the mechanisms governing pM141 stability. To assess 
whether the proteasome is required for the degradation of pM141, RVA140- or WT-
infected cells were treated with proteasome inhibitors and then steady-state levels of 
pM141 in the presence or absence of inhibitor were compared. To assess the contribution 
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of ubiquitination to pM141 degradation we immunoprecipitated pM141 in the presence 
or absence of proteasome inhibitor and looked for polyubiquitinated forms of the protein. 
Furthermore, we examined the steady-state levels of pM141 in cells containing a 
temperature-sensitive defect in the El ubiquitin-activating enzyme. To determine if 
pM140 can stabilize pM141 in a concentration-dependent manner we titrated increasing 
amounts of a M140-expression plasmid into RVA140-infected fibroblasts and compared 
the relative amount of pM141 levels. To assess whether complexing with pM140 is 
required for protecting pM141 from degradation we tested a panel of pM140 truncation 
mutants for their ability to complex with pM141 and then tested the ability of the mutants 
to stabilize pM141. 
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CHAPTER m 
INTERACTION DOMAIN MAPPING OF pM140 AND pM141 
Introduction 
Protein/protein interactions are involved in every aspect of cellular biology. 
These interactions may be transient or stable depending on the proteins involved and their 
function (87). Proteins rarely act in isolation and may function in small or large 
complexes or may form complexes as a means of regulation (3, 115). The binding sites 
of proteins may be specific for a single protein or may contain amino acids that make 
conserved interactions with numerous other proteins (87). Interaction domains may be 
dependent on conformation of the protein or may a linear within the sequence of the 
protein and rely on shape, chemical complementarity, and flexibility of the proteins 
involved (87). 
The M140 and M141 genes each express a single protein of 56 kDa and 52 kDa, 
respectively, and the transcripts and protein products are expressed with similar kinetics 
(59, 61). We have demonstrated that pM140 and pM141 are members of a stable 
complex also containing the products of an adjacent gene, pM139, and an unidentified 
protein of approximately 98 kDa (82). In addition to this larger complex, we have also 
demonstrated that a pM140/pM141 complex exists and can be isolated in the absence of 
pM139 (82). Given the importance of pM140 and pM141 in macrophage tropism, it is 
important to understand the extent to which the proteins function individually or in 
complex. We hypothesized that pM140 and pM141 complexing is required for function. 
To address this hypothesis we generated plasmid constructs with large deletions in each 
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of the genes that express N- and C-terminally deleted proteins. For each gene, each 
mutant construct was expressed in vitro and assayed for an ability to complex with the 
full-length binding partner. Mapping the interaction domains will allow us to generate 
mutant MCMV with interaction-defective alleles to assess the contribution of complexing 
in protein function. 
Materials and Methods 
Generation of plasmids. We generated plasmid constructs to express either full-
length or N- or C-terminally truncated pM140 for the purpose of expressing the proteins 
in in vitro transcription/translation reactions. A full-length (FL) construct of the MHO 
gene that expresses the protein with an N-terminal polyhistidine (His) and Xpress-epitope 
tag, Hisl40FL, was generated as previously described (82). The C-terminal truncation 
mutant, pHisHOApaSTOP, was generated via linker insertion mutagenesis. Briefly, the 
palindromic Bsu36ISTOP primer (Table 1) which contains a stop codon in all three 
frames was annealed to form double-stranded DNA. Specifically, 100 ug of primer was 
annealed in IX annealing buffer (200 mM Tris, pH 7.5, 500 mM sodium chloride, 100 
mM magnesium chloride) by incubating the mixture at 70°C for 10 minutes after which 
the primers were allowed to slowly equilibrate to room temperature. The linker DNA 
was then precipitated with 1/10 volume of sodium acetate and 2 volumes of ethanol. For 
the purpose of phosphorylating the linker DNA, approximately 10 |xg of the precipitated 
DNA was reacted with 5 units of T4 Polynucleotide Kinase (New England Biolabs) 
according to manufacturer's instructions. The phosphorylated linkers were ligated to 
Apal-digested Hisl40FL after the Apal site had been blunted by reacting the digested 
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DNA with 1 unit of T4 DNA polymerase (Invitrogen) in the presence of 0.1 mM dNTPs. 
The excess primer was removed and the DNA was religated to form the Hisl40ApaSTOP 
construct which expresses an N- terminally His/Xpress-tagged Ml40 protein deleted of 
62 C-terminal amino acids. 
TABLE 1. List of primers utilized in generating M140 and M141 plasmid constructs. Contents include 
the primer name, the DNA sequence of the primer, and the restriction endonuclease enzyme site introduced 














































































The remaining four M140 3' truncation mutants, 140USAcidic/TOPO, 
140DSM4/TOPO, 140USM4/TOPO, and 140DSM3/TOPO, were generated by PCR 
amplification of distinct regions within the M140 gene using the primer pairs listed in 
Table 2 with Hisl40FL (82) as template DNA. After amplication each PCR product was 
ligated into the TA cloning vector, pCR4-TOPO, (Invitrogen) as per manufacturer's 
directions and the resultant 140USAcidic/TOPO, 140DSM4/TOPO, 140USM4/TOPO, 
and 140DSM3/TOPO constructs are designed to express N-terminal His/Xpress epitope-
tagged fusion proteins deleted of 105,179, 259, 305 amino acids, respectively. The 
sequence of each truncated gene was verified. The orientation of each gene in the 
cloning vector was verified to assess which of the flanking promoters would drive in vitro 
expression (T3 for 140USAcidic/TOPO and 140USM4/TOPO; T7 for 140DSM4/TOPO 
and 140DSM3/TOPO). 
Ml 40 gene constructs truncated at the 5' end of the gene were generated similarly 
except that the pCR4-TOPO vector was used as an intermediate vector prior to 
subcloning. Distinct regions of the Ml40 gene from the HisHOFL (82) template were 
amplified by PCR (Table 2), the amplified products were ligated into pCR4-TOPO as 
instructed by the manufacturer, and the Ml40 gene sequence was verified to be correct. 
The truncated MHO gene products were digested out of the intermediate vector using the 
BamHI and NotI sites introduced by the primer sets (Table 1) and the fragments were 
resolved by electrophoresis on a 1% agarose gel. Each fragment was purified using the 
QIAquick Gel Extraction Kit (Qiagen) according to manufacturer's instructions and was 
ligated into BamHI/Notl-digested HisHOFL so that each mutant will be expressed as a 
fusion protein with an N-terminal His/Xpress epitope tag. The resulting 
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140ForUSMl/His, 140ForUSM2/His, 140ForUSM3/His, and 140ForDSM3/His 
constructs express Ml40 proteins deleted of 36, 76, 108, and 184 N-terminal amino 
acids, respectively. 
TABLE 2. Primer pairs used to generate 3' truncations of M141 and 5' or 3' truncations of M140 in the 
pCR4-TOPO background. Contents include the primer set (see Table 1) used to generate the plasmids 






























































We also generated plasmid constructs of the M141 gene that express C-terminally 
truncated proteins under control of a promoter to drive expression in in vitro 
transcription/translation reactions. A construct that expresses full-length pM141 as a 
FLAG-epitope N-terminal fusion protein under control of a mammalian expression 
promoter, FLAG-M141, was generated as previously described (82). Five 3' truncation 
mutants were generated using PCR to amplify regions of the Ml 41 gene using the F141 
(82) construct as a template (see Table 2 for the list of primers used in PCR reactions). 
Each PCR product was ligated into pCR4-TOPO as per manufacturer's instructions and 
the sequence of the M141 gene was verified. Each gene was determined to be under 
control of the T7 promoter. Each of the constructs is designed to be expressed as an N-
terminally-tagged FLAG epitope fusion protein. The FLAG141FL-T7 construct 
expresses full-length pM141 while the C-terminal truncation constructs, 
141MostCTerm/TOPO, 141NextCTerm/TOPO, 141DSM4/TOPO, 141USNLS/TOPO, 
and 141USM4/TOPO, express pM141 deleted of 59, 115, 176, 202, 251 amino acids, 
respectively. 
To generate a plasmid to express full-length pM140 as a GST fusion protein a 
BamHI to NotI fragment from Hisl40FL (82) was inserted into BamHI/Notl-digested 
pGEX-6P-2 (GE Healthcare) after the fragment was electrophoresed on 1% agarose and 
purifed using the QIAquick Gel Extraction Kit (Qiagen) according to manufacturer's 
instructions. This construct, GST140FL, expresses pM140 as an N-terminally tagged 
GST fusion. 
A plasmid was also constructed to express full-length pM141 as a glutathione S-
transferase (GST) fusion protein. The entire Ml41 gene was amplified by PCR using 
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F141 (82) as a template with the Forl41FLwSmaI and For 14 lFLwBamffl primers (Table 
1). The PCR product was ligated into pCR4-TOPO (as per manufacturer's instructions) 
as an intermediate vector. The sequence was verified and a Smal to BamHI fragment 
from the intermediate vector was inserted into Smal/BamHI-digested pGEX-6P-2 after 
the fragment was electrophoresed on a 1% agarose gel and purifed, according to 
manufacturer's directions, using the QIAquick Gel Extraction Kit (Qiagen). This 
construct, GST141FL, expresses full-length pM141 as an N-terminally tagged GST 
fusion protein. 
Two plasmids that express non-related proteins as GST fusions were used as 
negative controls for the GST pulldowns. A plasmid that expresses the human 
cytomegalovirus IE86 protein as an N-terminal GST fusion protein was a kind gift from 
Julie Kerry (Eastern Virginia Medical School, Norfolk, VA). A plasmid that expresses 
the interferon-inducible gene, IFI16, was a kind gift from Joseph Trapani (The Austin 
Research Institute, Victoria, Australia). 
Restriction Enzyme Digestion. All restriction enzymes (New England Biolabs) 
were used according to manufacturer's directions. Typically, between 5-15 units of 
enzyme per ug of DNA was used in digestions which were reacted at the appropriate 
temperature for 3 to 5 hours. 
Ligations. Wherever PCR products were ligated into the pCR4-TOPO vector 
using the TOPO TA Cloning Kit the ligations were performed as directed by the 
manufacturer. All other ligations were conducted using a minimum of a three fold molar 
ratio of insert to vector in the presence of 0.5 units of T4 DNA Ligase (Invitrogen) 
according to the manufacturer's instructions with an overnight incubation at 4°C. In the 
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case of linker insertation mutagenesis, approximately 1 ug of vector DNA was reacted 
with approximately 2.5 ug of phosphorylated linker in the presence of 5 units of T4 DNA 
Ligase and IX Blunt End Buffer (0.066 M Tris-Cl, pH 7.6, 5 mM magnesium chloride, 5 
mM dithiothreitol, 1 mM hexamminecobalt chloride, 0.2 mM ATP, 0.5 mM spermidine 
HCl)for24hoursat4°C. 
Transformations. All transformations were performed with chemically-
competent cells as described below. All transformations involving the pCR4-TOPO 
vector (Invitrogen) were performed in TOP 10 cells using the TOPO TA Cloning Kit for 
Sequencing (Invitrogen) as per manufacturer's instructions. The 5' Ml40 truncation 
mutants and GST140FL were transformed into XL-1 blue cells with 1 to 2 ul of ligated 
DNA after a 30 minute incubation on ice. The transformation was performed with a heat 
shock at 42°C for 1.5 minutes. After an incubation on ice for 2 more minutes 800 ul of 
SOC Medium (153) was added to cells for a 1 hour recovery at 37°C with agitation. 
Competent cells were prepared as per Sambrook (153). GST141FL was transformed into 
NovaBlue cells (Novagen) according to manufacturer's instructions. 
Polymerase chain reaction. PCR reactions were carried out with 20 pmol of 
forward and reverse primers and with 1 ng of template DNA using the Titanium Taq PCR 
Kit (Clontech) as per manufacturer's instructions except that 0.5 ul of DNA polymerase 
was used. Standard cycling conditions were as follows: 1 cycle of 95°C for 5 minutes; 
30 to 35 cycles of 95°C for 30 seconds, 60°C for 30 seconds, 72°C for between 2 and 2.5 
minutes; and 1 cycle of 72°C for 10 minutes on the MyCycler Thermal Gradient (Bio-
Rad). In generating the 5' truncation mutants of M140 it was necessary to alter the 
standard conditions as follows: 1 cycle of 95°C for 1 minute; 35 cycles of 95°C for 30 
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seconds, 68°C for 2 minutes; and 1 cycle of 72°C for 10 minutes. In certain cases it was 
necessary to perform gradient PCR using the standard conditions above except that 
instead of 60°C for 30 seconds a gradient of 50-65°C was used. 
Sequencing. Sequencing reactions were performed using the BigDye Terminator 
v3.1 Cycle Sequencing Kit (Applied Biosystems) according to manufacturer's 
instructions except that the ready reaction premix was diluted 1:16 before use. MHO or 
M141 gene inserts ligated into the pCR4-TOPO vector (see above) were sequenced using 
1 pmol of Ml 3 forward or reverse primers contained in the TOPO TA Cloning Kit (Ml 3 
primer sites flank the multiple cloning site of the vector) and, in some cases, the primers 
used to generate the PCR product ligated into the vector. In most cases the 
thermocycling conditions were as follows: 95°C for 30 seconds, 47° for 10 seconds, and 
60°C for 4 minutes for 34 cycles on a MyCycler Thermal Cycler. In other cases the 
following conditions were used to generate longer extensions: 15 cycles of 95°C for 10 
seconds, 47°C for 5 seconds, 60°C for 1 minute and 15 seconds; 5 cycles at 95°C for 10 
seconds, 47°C for 5 seconds, 60°C for 1 minutes and 30 seconds; 5 cycles at 95°C for 10 
seconds, 47°C for 5 seconds, 60°C for 2 minutes. Sequencing was performed on an ABI 
Prism 3130 Genetic Analyzer from Applied Biosystems. 
Amplification of plasmids. When plasmids were required for the purpose of 
screening cloned DNA by restriction enzyme digestion the plasmids were amplified by 
growing a single colony of transformed bacteria (see above) overnight at 37°C with 
agitation in 3 ml of Luria-Bertani Medium (LB (153)) containing either 0.2 mg/ml 
ampicillin (Sigma) or 50 u.g/ml kanamycin (Sigma) where appropriate. Approximately 
1.5 ml of overnight culture was pelleted by centrifugation at 14,000X g for 1 minute after 
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which the resulting pellet was resuspended in 100 fj.1 of Solution I (50 mM Tris, pH 8.0, 
50 mM glucose, 10 mM EDTA). After a 5 minute incubation on ice 200 ul of Solution II 
(0.2 M sodium hydroxide, 1% Trition X-100) was added to the sample. Cell lysis was 
allowed to proceed on ice until the cloudy solution began to clear (approximately 2-3 
minutes). The solutions were neutralized by addition of 150 ul of Solution in (3 M 
sodium acetate, pH 4.8). After a 5 minute incubation on ice the solutions were 
centrifuged for 5 minutes at 14,000X g. Supernatant was collected and incubated with 1 
volume of isopropanol for 5-10 minutes at room temperature. Plasmids were harvested 
by centrifugation at 14,000X g for 5-10 minutes. The plasmid-containing pellet was 
washed with 500 ul of 70% ethanol and pelleted as before. The dried pellet was 
resuspended in 50 ul of sterile water and then 10 ul was used per restriction digest. 
To generate large scale plasmid preparations the plasmids were first amplified in 
5 ml of starter culture of LB with 0.2 mg/ml ampicillin or 50 ug/ml kanamycin (where 
appropriate) overnight at 37°C with agitation. The starter culture was used to inoculate 
250 ml of LB containing the appropriate antibiotic which was incubated at 37°C with 
agitation for between 14-18 hours. Plasmids were purified using the Plasmid Maxi Kit 
(Qiagen) according to manufacturer's instructions. In some cases the Quantum Prep 
Plasmid Maxiprep Kit (Bio-Rad) was used to purify DNA. 
In vitro transcription/translations. Reactions were conducted using the TnT 
Coupled Reticulocyte Lysate System (Promega) with 30 uCi (Specific Activity 
>1000Ci/mM) of [35S] methionine or [35S] methionine/cysteine (GE Healthcare) 
according to manufacturer's directions in the presence of 40 units RNasin ribonuclease 
inhibitor (Promega). T3 or T7 RNA polymerase was used where indicated (see above). 
48 
To test expression of translated proteins, aliquots (2-5 ul) from each reaction were 
resolved on a 10-20% Gradient Tris-HCL Ready Gel (Bio-Rad) after boiling proteins for 
5 minutes in the presence of SDS-PAGE loading dye (5% glycerol, 1% SDS, 80 mM 
Tris-HCl, pH 6.8, 0.1% bromophenol blue) and 2 ul of 6-mercaptoethanol to denature the 
proteins. After electrophoresis the gel was fixed with three 20 minutes washes in 50% 
methanol/10% acetic acid solution, dessicated, and exposed to autoradiography film 
overnight. Films were developed using a SRX-101A Processor (Konica Minolta). 
Antibodies. Numerous antibodies were used to immunoprecipitate protein 
complexes. The generation of rabbit polyclonal antibodies raised against pM140 or 
pM141 has been previously described (61) and 5 ul of antibody or preimmune serum was 
utilized. We utilized 2 u,g of anti-HisG antibody (Invitrogen) or mouse IgG2a (Biodesign 
International, Saco, ME) as a negative control. In other experiments we utilized 2 ug of 
anti-FLAG M2 monoclonal antibody (Sigma) or mouse IgGltc (Sigma) as a negative 
control. 
Immunoprecipitations. Aliquots (between 2.5-40 ul) of in vitro translated 
proteins were diluted to 250 ul total volume in 10S Buffer (50 mM HEPES, pH 7.2, 250 
mM sodium chloride, 0.3% NP-40, 0.1% Triton-X-100, 0.005% SDS, 10 mM sodium 
phosphate, pH 7.0, 1 mM sodium fluoride, 0.1 mM phenylmethylsulfonyl fluoride 
(PMSF), 0.5 mM DTT) before being incubated with appropriate antibodies for 2 hours at 
4°C with rocking. The protein/antibody complexes were then incubated with 30 jil 
Protein A/G Plus Agarose (Santa Cruz) overnight at 4°C with rotation. Immune 
complexes were washed three times in SNNTE Buffer (50 mM Tris, pH 7.4, 5 mM 
EDTA, 0.5 M sodium chloride, 5% sucrose, 1% NP-40) and three times in RIPA buffer 
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(50 mM Tris, pH 7.4, 0.15 M sodium chloride, 1% Triton-X-100, 0.1% SDS, 1% 
deoxycholic acid) with centrifugations of 500X g at 4°C for 5 minutes between each 
wash. Protein complexes were denatured with 5 minutes of boiling in the presence of 
SDS-PAGE loading dye and 2 ul 6-mercaptoethanol prior to SDS-PAGE on 12.5% 
acrylamide gels. Detection of radiolabeled proteins was accomplished in one of two 
ways. In some cases, the gel was fixed with three 20 minutes washes in 50% 
methanol/10% acetic acid solution, dessicated, and exposed to autoradiography film for 
4-8 weeks after which films were developed using a SRX-101A Processor. In other 
cases, the dessicated gel was exposed to a phosphor screen for 1-3 weeks without fixation 
and then the phosphor screen was visualized on a Typhoon 9410 Variable Mode Imager 
(GE Healthcare). Protein analysis was performed using the ImageQuant TL Software. 
His pulldown assay with immobilized cobalt chelate. The ProFound Pull-
Down PolyHis Protein:Protein Interaction Kit from Pierce was utilized for these assays 
under two different experimental conditions. Under condition one the immobilized 
cobalt chelate was equilibrated as per manufacturer's instructions except that washes 
were performed with 250 ul buffer and subsequent centrifugations at 500X g at 1 minute 
each. Twenty microliters of each in vitro translated protein (see above) was mixed 
together for 2 hours at 4°C with rotation to allow complexing after the sample volume 
was brought to 250 ul total volume with BupH Tris buffered saline contained in the kit 
with 40 mM imidazole added. After this incubation 50 ul of equilibrated cobalt chelate 
was incubated with the samples overnight at 4° with rotation. Samples were pelleted by 
centrifugation at 500X g for 5 minutes at 4°C and pellets were subjected to three washes 
in SNNTE buffer containing 40 mM Imidazole followed by three washes in RIPA buffer 
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containing 40 mM Imidazole. After pelleting, the protein complexes were denatured with 
5 minutes of boiling in the presence of SDS-PAGE loading dye and 2 ul 13-
mercaptoethanol prior to SDS-PAGE on 12.5% acrylamide gels. 
In other cases, experiments were conducted under the same conditions with the 
exception that 10S Buffer was used to equilibrate the cobalt chelate and was used to bring 
the mixed proteins up to volume to allow complexing. Furthermore, all post-pulldown 
washes were performed with the buffers described above except that imidazole was not 
added. 
Detection of radiolabeled proteins was accomplished by exposing the dessicated 
gel to a phosphor screen for 1-3 weeks following visualization of the screen on a 
Typhoon 9410 Variable Mode Imager. 
Preparation of GST and GST Fusion Proteins. One hundred nanongrams of 
plasmid expressing GST alone (pGEX-6P-2) or GST fusion proteins was transformed 
into chemically-competent BL21 cells via a heat shock of 42°C for 2.5 minutes after an 
incubation of 30-40 minutes on ice. Subsequent to heat shock the cells were incubated in 
1 ml of LB (153) for 1 hr at 37°C with agitation. Single colonies, isolated after plating 
between 100 to 150 ul of the transformed cells on LB/agar plates containing 0.2 mg/ml 
ampicillin (Sigma), were used to inoculate a 5 ml starter culture of LB with 02. mg/ml 
ampicillin which was incubated overnight at 37°C with agitation. The following day the 
entire starter culture was used to inoculate 250 ml of LB with 0.2mg/ml ampicillin which 
was incubated at 37°C with agitation until the optical density at 550 nm reached 0.8-1.0. 
The cells were incubated as before for an additional 4 hrs in the presence or absence of 
ImM isopropyl B-D-1-thiogalactopyranoside (Fisher Scientific) after which the bacterial 
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cells were pelleted. Each pellet was resuspended in 25 ml of Buffer A (20 mM HEPES, 
pH 7.5, 0.1 M potassium chloride, 0.2 mM EDTA, pH 8.0, 20% glycerol, 1% Triton X-
100, 1 mM DTT, 1 mM PMSF) and was then sonicated to lyse the cells. Sonications 
were performed with a Fisher Scientific Sonic Dismembrator Model 100 using a 1/8 inch 
tip with four 13 watt pulses for 30 seconds each. Cellular debris was separated by 
centrifugation at 19,837X g for 10 minutes at 4°C. The supernatant, containing proteins 
of interest, was reserved for use in GST pulldown assays. 
Purification of GST-tagged Proteins and GST Pulldown Assays. GST fusion 
proteins were precipitated using Glutathione Sepharose (GE Healthcare) according to 
manufacturer's instructions. Specifically, 400 ul of glutathione sepharose was mixed 
with each aliquot of the prepared GST protein samples (see above) for 2 hours at 4°C 
with rotation. The GST protein/Glutathione Sepharose complexes were washed five 
times in NETN Buffer (0.5% NP-40, 20 mM Tris, pH 8.0, 100 mM sodium chloride, 1 
mM EDTA) after pelleting for 5 minutes at 500X g. After the final wash the pellet was 
resuspended in 150 ul of NETN. A 20 ul aliquot of each precipitated protein was 
resolved on a 10-20% Gradient Tris-HCL Ready Gel (Bio-Rad) after pelleting and 
denaturing by boiling for 5 minutes in the presence of SDS-PAGE loading dye and 2 ul 
of B-mercaptoethanol. The gel was fixed with two 15 minutes washes in 50% 
methanol/10% acetic acid solution. After overnight staining with SYPRO Ruby Protein 
Gel Stain (Invitrogen, 1:1 SYPRO Ruby/water) the gel was visualized on the Kodak Gel 
Logic 200 Imaging System and the amount of pGST140FL or pGST141FL was 
quantitated relative to that of each negative control proteins (GST, GSTIE86, GSTIFI16) 
using ImageQuant TL Software. 
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In order to precipitate in vitro translated proteins (see above) the purified GST 
fusion protein/glutathione sepharose complexes were mixed with 20 ul of lysate 
containing radiolabeled protein for 2 hours at 4°C with rotation. Before mixing, volumes 
containing relative quantities of purified pGST140FL or pGST141FL to that of negative 
control proteins (no more than 50 ul total volume) were first equilibrated with 500 ul 
Binding Buffer (25 mM HEPES, pH 7.5, 12.5 mM magnesium chloride, 20% glycerol, 
0.1% NP-40, 150 mM potassium chloride, 0.15mg/ml bovine serum albumin, 1 mM 
DTT) by centrifugation of 500X g for 5 minutes at 4°C and then the pellet was 
resuspended in 200 ul fresh binding buffer. After mixing, the complexes were washed 
three times in either NETN, SNNTE, or RIPA buffer or were washed three times in 
SNNTE followed by three RIPA washes (as indicated in results) with centrifugations of 
500X g at 4°C for 5 minutes between each wash. Protein complexes were denatured and 
resolved by SDS-PAGE on 12.5% acrylamide gels. Detection of radiolabeled proteins 
was accomplished by exposing the dessicated gel to a phosphor screen for 1-3 weeks 
following visualization of the screen on a Typhoon 9410 Variable Mode Imager. Protein 
analysis was performed using the ImageQuant TL Software. 
Results 
Interaction domain mapping of pM141. We had previously demonstrated that 
pM140 and pM141 form a stable complex (82) and we wanted to determine which 
region(s) of pM141 were required for binding. M141 is a member of the US22 family 
found in all beta-herpesviruses and is characterized by having up to four conserved 
motifs (21, 39, 59, 94, 119, 120, 143). The M141 protein contains all four motifs (Fig. 3 
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(59)). Although a function for the motifs has not been identified the conserved nature of 
the motifs implies that they impart an important property for the proteins. Thus, we 
targeted these motifs in our deletional analysis (Fig. 7). For this purpose we generated 
large scale deletions at the 5' and 3'ends of the gene. Full-length and each of the deletion 
mutants were expressed as epitope tag fusion proteins so that we could capture the 
proteins via the epitope tag without the concern of deleting the epitope(s) recognized by 
rabbit polyclonal antibodies (61). 
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FIG. 7. Diagram showing the panel of pM141 C-terminal deletion mutants generated to map the 
interaction domain of the protein. Full-length pM141 is shown at the top along with the location of the 
US22 Motifs (open boxes), the NLS (hatched box) which shares some overlap with motif IV, and the PEST 
motif (white box). The ruler is shown for reference with each tick mark corresponding to 10 amino acids. 
Each pM141 deletion mutant is shown drawn to scale with the location of the FLAG epitope tag (not drawn 
to scale). 
Specifically, we generated a construct that expresses full-length pM141 as an N-
terminally tagged FLAG epitope fusion protein, FLAG141FL-T7. We have previously 
shown that a pM141/FLAG epitope fusion protein retained the ability to complex with 
pM140 when the proteins were transiently expressed in fibroblasts (82). 
Constructs were also generated with deletions in M141 from the 3' end of the 
gene that express each deletion mutant protein as a fusion protein with an N terminal 
FLAG tag (Fig. 7). The pl41MostCTerm/TOPO and pl41NextCTerm/TOPO mutants 
retain all four US22 Motifs and are deleted of 59 and 115 amino acids, respectively. The 
pl41DSM4/TOPO mutant is deleted of 176 amino acids downstream of the putative 
NLS. The mutant, pl41USNLS/TOPO, is deleted of the putative NLS and 202 C-
terminal amino acids. The pl41USM4/TOPO mutant, deleted of the NLS and Motif IV, 
is missing 251 amino acids. 
We first sought to determine if pFLAG141FL-T7 and the deletion mutants could 
be expressed in vitro. Each of the protein products was expressed from coupled 
transcription/translation reactions as [35S] methionine labeled products. The full-length 
and C-terminally truncated products were efficiently expressed and predominantly two 
protein products were translated (Fig. 8). The native start codon of M141 is present in 
each of the plasmid constructs. Therefore, the higher molecular weight and predominant 
product most likely represents the FLAG epitope fusion protein generated from the start 
codon upstream of the FLAG tag while the lower molecular weight product most likely 
represents protein generated from the native M141 start codon that does not contain the 
epitope tag (Fig. 8). 
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FIG. 8. Expression of in vitro translated full-length and C-terminally truncated pM141 mutants. 
Plasmids that express FLAG141FL-T7 (FL) M141,141MostCT/TOPO (MostCT), 141NextCT/TOPO 
(NextCT), 141DSM4/TOPO (DSM4), 141USNLS/TOPO (USNLS), or 141USM4/TOPO (USM4) were 
expressed from coupled transcription/translation reactions using rabbit reticulocyte lysates in the presence 
of [3SS] methionine/cysteine. A negative control (Control) reaction was performed without addition of 
plasmids. A fraction from each of the reactions was loaded onto a SDS-PAGE gel, electrophoresed, and 
exposed to x-ray film for an overnight exposure. Asterisk (*) shows proteins expressed without the FLAG 
epitope tag while arrows ( • ) is indicates proteins expressed with the FLAG epitope fusion. 
We next sought to determine if an in vitro translated, His epitope-tagged, full-
length pM140 construct, pHisl40FL, could be immunoprecipitated with pFLAG141FL-
T7 or the C-terminally truncated pM141 mutants using an anti-FLAG antibody to capture 
the FLAG epitope fused to each of the pM141 constructs. We have previously 
demonstrated that the His epitope tag in Hisl40FL does not interfere with complex 
formation (82). We tested a panel of the pM141 mutants including pFLAG141-T7, 
pl41DSM4/TOPO, and pl41USM4/TOPO where each of them was co-expressed with 
pHisl40FL the co-translated proteins were subjected to immunoprecipitation with either 
the anti-FLAG antibody or IgGl which is the isotype-matched control. Each construct 
was efficiently co-expressed with pHisl40FL (Fig. 9, input). Two predominant products 
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FIG. 9. Anti-FLAG antibody immunoprecipitations of co-translated pHisl40FL and either 
pFLAG141FL-T7 (FLAG141FL), pl41DSM4/TOPO (FLAG141DSM4), orpl41USM4/TOPO 
(FLAG141USM4). The Hisl40FL protein was co-expressed with each of the pM141 mutants shown above 
using coupled transcription/translation reactions with rabbit reticulocyte lysates in the presence of [35S] 
methionine. The resulting proteins were loaded directly onto SDS-PAGE for analysis (input) or were first 
subjected to immunoprecipitations with either anti-FLAG antibody or isotype-matched control antibody 
(IgGl) as indicated. Arrows point to the location of each of the epitope-tagged proteins as indicated as well 
as pM140 expressed without the His tag fusion (140FL) and pM141 expressed without the FLAG tag 
fusion (141FL). 
were consistently produced from pHisl40FL. The higher molecular weight product 
represents His-tagged pM140 while the lower molecular weight product most likely 
represents pM140 without the His epitope fusion tag as expressed from the native start 
codon that is still present in the construct. Similarly, and as seen in Fig. 8, the 
predominant and higher molecular weight product of each of the pM141 constructs 
represents the FLAG epitope- tagged protein and a lower molecular weight product was 
also seen representing each construct minus the tag. We also observed some additional 
lower molecular weight products expressed from each construct and they most likely 
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represent breakdown products of pHisl40FL, the pM141 mutants, or both. As expected, 
we were able to precipitate significant amounts of each of the FLAG-tagged pM141 
mutants with the anti-FLAG antibody. However, IgGl also precipitated a significant 
amount of each of the pM141 mutants and to a lesser extent, pHisl40FL. Thus, we were 
unable to confirm complexing between even full-length pM141 and pM140 because the 
level of binding with the isotype-matched control is too high. 
The results from Fig. 9 implied that there was a significant amount of binding of 
our proteins with the IgGl control and that, as a consequence, the anti-FLAG antibody 
may be able to non-specifically precipitate native pM141 and pHisl40FL. This led us to 
test the extent to which protein was brought down non-specifically with the anti-FLAG 
antibody. Thus, we performed immunoprecipitations of the native, non-tagged pM141 
and of pHisl40FL in the presence or absence of pM141. We found that the anti-FLAG 
antibody precipitated a comparable amount of pHisHOFL regardless of whether 
pFLAG141FL-T7 was expressed (Fig. 10, left panel). We were also able to precipitate 
native pM141 with the anti-FLAG antibody despite the fact that the protein does not 
contain the FLAG epitope (Fig. 10, right panel). The combined results from Fig. 9 and 
Fig. 10 demonstrated that background binding of pM140 to the anti-FLAG antibody is 
too high to allow us to use anti-FLAG immunoprecipitations of the FLAG-tagged 











FIG. 10. Anti-FLAG immunoprecipitations of tagged and non-tagged pM140 in the presence or absence 
of pM141. In the left panel pHisl40FL was expressed individually or with pFLAG141FL-T7 
(FLAG141FL) while in the right panel native pM 140 (140FL) was co-expressed with native pM141 
(141FL) using coupled transcription/translation reactions with rabbit reticulocyte lysates in the presence of 
[35S] methionine. The resulting proteins were loaded directly onto SDS-PAGE for analysis (input) or were 
first subjected to immunoprecipitations with anti-FLAG antibody. 
Thus, we next sought to determine if the pM141 deletion mutants could be 
precipitated with the anti-His antibody when the proteins were co-expressed with 
pHisl40FL. The mutant proteins, FLAG141FL-T7, 141DSM4/TOPO, 
141USNLS/TOPO, and 141USM4/TOPO, were co-expressed with pHisl40FL and the 
products were subjected to immunoprecipitations with anti-His antibody. As shown in 
Fig. 11, each of the constructs was efficiently expressed in the assay and the anti-His 
antibody was able to specifically precipitate the pHisl40FL. Unfortunately, the control 
antibody, IgG2a, non-specifically bound to and precipitated significant amounts of 
pFLAG141FL-T7 as well as each of the pM141 deletion mutants. Furthermore, the 
quantity of each pM141 mutant protein that was brought down with anti-His was 
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comparable to that of the quantity precipitated with IgG2a so that the results cannot be 
accurately interpreted. 
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FIG. 11. Anti-His immunoprecipitations of pHisl40FL co-expressed with pFLAG141FL-T7 
(FLAG141FL), pl41DSM4/TOPO (FLAG141DSM4), pl41USNLS/TOPO (FLAG141USNLS), or 
pl41USM4/TOPO (FLAG141USM4). The Hisl40FL protein was co-expressed with each of the pM141 
mutants shown above using coupled transcription/translation reactions with rabbit reticulocyte lysates in 
the presence of [35S] methionine. The resulting proteins were loaded directly onto SDS-PAGE for analysis 
(input) or were first subjected to immunoprecipitations with either anti-His antibody or isotype-matched 
control antibody (IgG2a) as indicated. Arrows point to the location of each of the epitope-tagged proteins 
as indicated as well as pM140 expressed without the His tag fusion (140FL) and pM141 expressed without 
the FLAG tag fusion (141FL). 
Given that the isotype-matched control to the anti-His antibody was able to non-
specifically precipitate the FLAG-tagged pM141 constructs, we next assessed the extent 
to which pFLAG141FL-T7 could be brought down non-specifically with the anti-His 
antibody in the absence of pHisl40FL. We also tested native pM141 in the assay in the 
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event that anti-His was binding non-specifically to the FLAG epitope of the 
pMl41 constructs rather than binding to a pM141 epitope. We found that even in the 
absence of pHisl40FL anti-His antibody precipitated clearly detectable levels of pM141 
expressed with or without the FLAG epitope tag (Fig. 12). The combined results of Fig. 
11 and Fig. 12 demonstrated that background binding of the pM141 deletion mutants to 
the anti-His antibody was too high to use the antibody in immunoprecipitations assays 
with pHisl40FL as a means of mapping the interaction domain of pM141. 
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FIG. 12. Immunoprecipitations of native pM141 (141) or pFLAG141FL-T7 (FLAG141) with anti-His 
antibody. Native pM141 or pFLAG141 were expressed as indicated from coupled transcription/translation 
reactions with rabbit reticulocyte lysates in the presence of [35S] methionine/cysteine. The resulting 
proteins were loaded directly onto SDS-PAGE (input) or were first subjected to immunoprecipitations with 
anti-His antibody. 
Given the degree of non-specific binding of the antibodies in 
immunoprecipitations we next turned to pulldown assays with the ProFound Pull-down 
PolyHis Protein:Protein Interaction Kit from Pierce in an attempt to pulldown pM141 co-
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expressed with pHisl40FL. The Profound system relies on a cobalt chelated affinity gel 
to recognize His-tagged proteins rather than anti-His antibodies. We first performed the 
assay with native, full-length pM141 with the long-term goal of mapping the pM141 
interaction domain(s) using our FLAG-tagged pM141 deletion mutants. As seen in Fig. 
13 and as expected, pHisl40FL was brought down in the assay regardless of the presence 
of pM141. Unfortunately, even in the absence of pHisl40FL, pM141 was pulled down 
non-specifically in quantities at least as great as that of pM141 co-expressed with 
pHisHOFL. This was true regardless of whether imidazole was added to the wash 
buffers to reduce non-specific binding. In fact, addition of imidazole actually enhanced 
binding of pM141 regardless of the presence of pHisl40FL. This result demonstrated 
that background binding of pM141 to the cobalt chelate was too high to use in a His tag 
pulldown of pHisl40FL for the purpose of mapping the pM141 interaction domain(s). 
• Imidazole + Imidazole 




HIS140FL HIS140FL 141 PL 141FL HIS140FL 141 FL 141FL 
iJL -m 
FIG. 13. Pierce ProFound pulldown assay of full-length, native pM141 (141FL) in the presence or 
absence of pHisl40FL. The Hisl40FL protein was co-expressed with pl41FL or where indicated the 
proteins were expressed individually. Proteins were generated using coupled transcription/translation 
reactions with rabbit reticulocyte lysates in the presence of [35S] methionine/cysteine. The labeled proteins 
were loaded directly onto SDS-PAGE for analysis (input) or were first subjected to the pulldown assay and 
were washed in buffers in the presence or absence of imidazole as indicated. 
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Thus, we next sought to determine if the pM141 interaction domain(s) could be 
mapped by utilizing GST pulldowns assays with GST-tagged pM140 construct 
(pGST140FL). These assays were performed by reacting in vitro translated 
pFLAG141FL-T7 with pGST140FL amplified in and harvested from K coli. As seen in 
Fig. 14A, pFLAG140FL-T7 was brought down with pGST140FL. Unfortunately, 
A. 
^ <£ <P cT 
B. 
SNNTE/ 
NETN RIPA SNNTE RIPA 
& »fi „o& ^ *$> ..iP dr ^ dr -tP dr *& «s 
FIG. 14. GST pulldown assays of pGST140FL (GST140) and pFLAG141FL-T7. TheGST140, 
GSTIE86, and GSTTfll6 proteins were amplified in E. coli, harvested, and subjected to pulldown with 
glutathione sepharose. The FLAG140FL-T7 protein was generated using coupled transcription/translation 
reactions with rabbit reticulocyte lysates in the presence of [35S] methionine/cysteine. The labeled protein 
was loaded directly onto SDS-PAGE for analysis (input) or was first subjected to pulldown with purified 
GST fusion proteins as indicated. A. Pulldown assays were performed using NETN to wash the samples. 
B. Pulldown assays were performed as in A, but also using the indicated buffers (RIPA, SNNTE, or both) 
for washing. 
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equivalent amounts of the protein were also brought down with two negative control 
proteins expressed as GST fusions, GSTEE86 and GSTIFI16 We also tested different 
wash buffers in conjunction with our pulldown assays to see if we could reduce the 
amount of non-specific binding of pFLAG141FL-T7. We found that there was a large 
degree of non-specific pFLAG141FL-T7 binding regardless of whether washes were 
performed with NETN, RIPA, SNNTE, or SNNTE followed by RIPA (Fig. 14B). These 
results demonstrated that background binding of pFLAG141FL-T7 to our negative 
control proteins was too high to use GST pulldown assays with pGST140FL to map 
pM141 interaction domain(s). 
Interaction domain mapping of the pM140 protein. Simultaneous to our 
experiments with pM141, we performed experiments to map the interaction domain of 
pM140. For this purpose we generated large scale 5' and 3' deletions in the M140. We 
also generated a mutant, Hisl40ApaSTOP, which has a stop codon introduced at the 3' 
end of the gene. The full-length and deletion mutants were expressed as an N-terminally 
tagged, His epitope fusion proteins (Fig. 15). MHO is also a member of the US22 family 
(59) and contains all four motifs characteristic of the family (Fig. 3). As with pM141, we 
targeted these motifs in our deletional analysis (Fig. 15). In addition, pM140 contains a 
region rich in acidic amino acids (Fig. 3) and this acidic domain was also targeted. The 
140ForUSMl/TOPO construct expresses a mutant protein that retains all four US22 
motifs, but is missing the first 36 N-terminal amino acids. The 140ForUSM2/TOPO 
mutant is deleted of 76 N-terminal amino acids including US22 Motif I and the 
140ForUSM3/TOPO is deleted of 108 N-terminal amino 
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FIG. IS. Diagram ofthe panel ofpM140N-and C-terminal deletion mutants screened for an ability to 
interact with pM141. Full-length pM140 is shown at the top along with the location ofthe US22 motifs 
(filled blocks) and the acidic domain (AD). The ruler is shown for reference with each tick mark 
corresponding to 10 amino acids. Each pM140 deletion mutant is shown drawn to scale with the location 
ofthe His epitope tag (not drawn to scale). 
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acids including Motifs I and II. The 140ForDSM3 mutant is deleted of Motifs I, II, and 
HI and 184 N-terminal amino acids. The Hisl40ApaSTOP construct expresses a mutant 
protein deleted of 62 C-terminal amino acids adjacent to the acidic domain while the 
140USAcidic/TOPO mutant is missing 105 amino acids including the acidic domain. 
The 140DSM4/TOPO construct is missing 179 C-terminal amino acids adjacent to Motif 
IV while this motif is deleted of 259 amino acids along with Motif IV. The 
140DSM3/TOPO mutant is missing 305 C-terminal amino acids adjacent to Motif HI. 
We first asked if the pM140 mutants could be efficiently expressed in vitro. For 
this purpose each of the plasmid constructs was added to coupled in vitro 
transcription/translation reactions in the presence of [35S] methionine/cysteine and the 
resultant proteins were analyzed by SDS-PAGE. The Hisl40FL protein and each of the 
N-terminal deletion mutants were expressed efficiently (Fig. 16, left panel). Each of the 
C-terminal deletion mutants was expressed to levels that were clearly detectable (Fig. 16, 
right panel). In general, the C-terminal deletion mutants are deleted of more methionines 
and cysteines than the N-terminal deletion mutants and thus, are not labeled to an 
equivalent extent. This fact is reflected in the levels of C-terminal deletion mutants 
detectable relative to that of the N-terminal deletion mutants. 
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FIG. 16. Expression of in vitro translated full-length and either N-terminally truncated (left panel) or C-
terminally truncated (right panel) pM140 mutants. Plasmids that express Hisl40FL (FL), 
140ForUSMl/TOPO (ForUSMl), 140ForUSM2/TOPO (ForUSM2), 140ForUSM3/TOPO (ForUSM3), 
140ForDSM3/TOPO (ForDSM3), Hisl40ApaSTOP (ApaSTOP), 140USAcidic/TOPO (USAcidic), 
140DSM4/TOPO (DSM4), 140USM4/TOPO (USM4), and 140DSM3/TOPO (DSM3) were expressed from 
coupled transcription/translation reactions using rabbit reticulocyte lysates in the presence of [ S] 
methionine/cysteine. A fraction from each of the reactions was loaded onto a SDS-PAGE gel, 
electrophoresed, and exposed to x-ray film for an overnight exposure. 
Next, we performed GST pulldown assays to determine which of the pM140 
deletion mutants retained an ability to complex with full-length, GST-tagged pM141, 
pGST141FL. We first examined the binding of full-length pM140 and found that 
pHisHOFL was able to bind efficiently to pGST141FL (Fig. 17). Although we did 
observe background binding of pHisl40FL to the negative control protein (GSTEE86), 
when the amount of GST141FL-bound H3sl40FL was quantitated and compared to that 
of GSTIE86-bound pHisl40FL we observed a small, but consistent increase. These 
results demonstrate that there is specific binding of pHisHOFL to pGST141FL. When 
we tested the N-terminal mutants in our assay we found that each of the mutants was 
expressed efficiently and exhibited similar levels of binding to pGST141FL as to that of 
GSTIE86 (Fig. 17A). When background binding was subtracted and binding levels were 
67 
A. 
140FL 140ForUSM1 140FortJSM2 140ForUSM3 140ForDSM3 
<£> <£ Jv 
y //*//*//*//*// 
* 
& # & ^ tf 
• 
FIG. 17. GST pulldown assays of pGST141FL (GST141) and the pM140 N-terminal deletion mutants. 
The GST141 and GSTIE86 proteins were amplified in E. coli, harvested, and subjected to pulldown with 
glutathione sepharose. The Hisl40FL and MHO deletion mutant proteins were generated using coupled 
transcription/translation reactions with rabbit reticulocyte lysates in the presence of [3SS] 
methionine/cysteine. The labeled proteins were loaded directly onto SDS-PAGE for analysis (input) or 
were first subjected to pulldown with purified GST fusion proteins as indicated. A. Radiographs of 
pHisl40FL (140FL), pl40ForUSMl/TOPO (140ForUSMl), pl40ForUSM2/TOPO (140ForUSM2), 
pl40ForUSM3/TOPO (140ForUSM3), and pl40ForDSM3/TOPO (140ForDSM3). B. Quantitation of 
pulldown assays of the mutants are shown after background binding to GSTIE86 was subtracted. 
Quantitation is shown as percent binding where pHisl40FL is set to 100%. 
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quantitated and compared to levels of pEfisl40FL binding, we found that binding was 
nearly or completely abolished with each of the N-terminal deletion mutants (Fig. 17B). 
These results demonstrate that the 36 most N-terminal amino acids of pM140 contain an 
interaction domain. When we tested the C-terminal mutants in our assay we found that 
pHisHOApaSTOP and pl40USAcidic/TOPO had binding at least as comparable as 
pHisl40FL, but that each mutant deleted of further C-terminal amino acids had 
significantly reduced binding to pGSTHlFL (Fig. 18A). In fact, upon quantitation, we 
found that pHisHOApaSTOP and pl40USAcidic/TOPO exhibited increased binding 
relative to pHisl40FL while pl40DSM4/TOPO and pl40DSM3/TOPO only bound to 
18% or 5% of pHisl40FL levels, respectively (Fig. 18B). The 140USM4/TOPO protein 
retained some binding ability relative to the flanking mutants at 67% binding of 
pHisl40FL (Fig. 18B). These results demonstrate that the internal amino acids 180-306 
of pM140 are required for optimal binding to pM141. 
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FIG. 18. GST pulldown assays of pGST141FL (GST141) and the pM140 C-terminal deletion mutants. 
The GST141 and GSTIE86 proteins were amplified in K coli, harvested, and subjected to pulldown with 
glutathione sepharose. The Hisl40FL and M140 deletion mutant proteins were generated using coupled 
transcription/translation reactions with rabbit reticulocyte lysates in the presence of [35S] 
methionine/cysteine. The labeled proteins were loaded directly onto SDS-PAGE for analysis (input) or 
were first subjected to pulldown with purified GST fusion proteins as indicated. A. Radiographs of 
pHisl40FL (140FL), pHisHOApaSTOP (140ApaSTOP), pl40USAcidic/TOPO (140USAcidic), 
P140DSM4/TOPO (140DSM4), pl40USM4/TOPO (140USM4), and pl40DSM3/TOPO (140DSM3). B. 
Quantitation of pulldown assays of the mutants are shown after background binding to GSTIE86 was 
subtracted. Quantitation is shown as percent binding where pHisl40FL is set to 100%. 
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Discussion 
The M140 and M141 proteins are members of at least two complexes inside 
infected cells (82) suggesting that the proteins may function in complex. We sought to 
map the interaction domains of the proteins. This would provide us with the tools to 
generate MCMV with an interaction-defective allele so that we can determine the extent 
to which complexing affects the function of the proteins in macrophage tropism. 
pM141 Interaction Domain Mapping. We were unable to map the domain of 
pM141 that confers binding to pM140. In each of the assays we tested and under each 
experimental condition we observed non-specific binding in quantities that made us 
unable to accurately interpret our results. 
Immunoprecipitations were not a viable option to pull down our proteins of 
interest for interaction domain mapping. We observed non-specific binding between 
pM140 and the anti-FLAG antibody and between pM141 with the anti-His antibody. 
This was true regardless of whether the target proteins were fused to epitope tags. 
We were not able to utilize a His pulldown assay in conjunction with an 
immobilized cobalt chelate to map the interaction domains. We found that more pM141 
was pulled down in the absence of His-tagged pM140 than in the protein's presence. 
This was true even in the presence of elution compound added to reduce non-specific 
binding. 
We were unable to map the interaction domains of pM141 using GST pulldown 
assays with GST-tagged pM140. We found that pM141 bound non-specifically to our 
negative control proteins, GST-tagged IE86 and GST-tagged BFI16, to levels comparable 
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to that seen with binding to GST-tagged pM140. IE86 is a non-related HCMV viral 
protein that is a transcriptional activator of the HCMV DNA polymerase gene, UL54, as 
well as other viral and cellular promoters (173). EFI16 is a cellular protein that inhibits 
cell cycle progression, regulates the DNA damage response, and represses transcription 
of UL54 (79, 129). Binding of pM141 or pM140 to IE86 or IFI16 is not predicted since 
microarray analysis of cells infected with a mutant virus deleted of M139, M140, and 
M141 did not reveal differences in viral gene expression compared to WT-infected cells 
(unpublished observation). Furthermore, we have shown that pM140 functions indirectly 
to stabilize viral capsids (60). Thus, binding of pM141 or pM140 to IE86 or IFI16 is 
most likely truly nonspecific. 
Our combined results indicate that pM141 expressed in vitro, rather than 
achieving the proper conformation, is a globular protein that can bind non-specifically 
with at least moderate affinity to non-interacting protein partners including antibodies. 
Given this assumption, in vitro-expressed pM141 would bind non-specifically to 
additional antibodies and proteins. However, we have previously demonstrated that 
pM141 expressed from in vitro coupled transcription/translation reactions did not 
crossreact with our polyclonal antibodies, anti-M139 or anti-M140 (61). Thus, although 
we did not pursue these experiments, it may be possible to map the interaction domain(s) 
using immunoprecipitation assays with anti-M140 to pull down pM141 with native 
pM140. 
We have previously immunoprecipitated the larger complex of His-
tagged/pM139, pM140, and pM141 from fibroblasts transiently expressing the proteins 
using an anti-His antibody (82). Under these conditions, we did not observe non-specific 
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binding of the proteins to the anti-His antibody. In addition, we do not observe 
significant binding of transiently expressed FLAG-M141 to our anti-M140 antibody in 
the absence of pM140 (82). Thus, another feasible approach may be to map the 
interaction domain from pM141/pM140 constructs expressed transiently in cultured cells 
in conjunction with immunoprecipitations assays. 
pM140 Interaction Domain Mapping. We identified two distinct regions of 
pM140 that are essential for optimal binding to pM141 in vitro. One of the regions is at 
the extreme N terminus of the protein and the second comprises 126 internal amino acids 
in the C-terminal half of the protein. Our results demonstrate that the pM140 interaction 
domain is non-contiguous and that pM140 can only complex with pM141 if the protein is 
in the proper conformation so that pM141 can make contact with both interaction 
domains. 
An alternative explanation is that only one interaction domain exists in the protein 
at the extreme N terminus and that the 126 internal amino acids are required for proper 
pM140 folding. We found that if we removed the 36 most N-terminal amino acids of 
pM140 the protein could not bind to pM141. If any further N-terminal amino acids were 
removed the results were identical. However, our results with the C-terminal mutants 
were more variable. We observed binding with two deletion mutants missing fewer C-
terminal amino acids (up to 105 amino acids removed). When further internal amino 
acids were removed, resulting in a total of 179 amino acids removed from the C terminus, 
binding was abolished. Interestingly, we recovered some binding with the adjacent 
mutant deleted of 259 amino acids, but binding was abolished again with a mutant 
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deleted of 305 amino acids. These results may indicate that the internal amino acids are 
required for proper protein folding. Under this assumption, deletion of 179 or 305 total 
amino acids results in a conformation that does not allow access of the N-terminal 
interaction domain to pM141. Deletion of 259 amino acids allows the truncation mutant 
to fold in a conformation that allows the N terminus to be exposed to pM141. 
We performed our interaction domain mapping using screens of proteins 
generated from in vitro translations. These results should be confirmed in cells 
expressing the proteins from transient transfections and infections so that the proteins are 
translated and expressed under native conditions. Presently, we have not tested the N-
terminal mutants for their ability to bind pM141 in cultured cells. However, these 
experiments have been performed with the relevant C-terminal mutants (see Chapter V) 
and the results support the hypothesis that the C terminus may confer conformation rather 
than binding to pM141. 
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CHAPTER IV 
LOCALIZATION DOMAIN MAPPING OF pM141 
Introduction 
The majority of nucleocytoplasmic shuttling of proteins is regulated as a means 
for functional compartmentalization in the cell (199). The shuttling occurs through 
nuclear pore complexes embedded in the dual membrane of the nuclear envelope. 
Directed transport of proteins in and out of the nucleus is typically controlled by specific 
signals, NLSs and NESs, in the primary sequence of the protein (199). Soluble transport 
receptors bind directly to the signal sequences and then interact with the nuclear pore 
complexes to import or export the cargo proteins (199). In other cases adaptor molecules 
bind to the signal sequences and are themselves bound by the transport receptors (199). 
Directionality of transport is controlled by a small guanine triphosphatase (GTPase), Ran, 
and its associated factors (75, 199, 200). Export receptors bind cargo in complex with 
RanGTP in the nucleus where the RanGTP levels are highest. Their cargo is released in 
the cytoplasm upon hydrolysis of RanGTP to RanGDP. The receptor and RanGDP are 
recycled to the nucleus. On the other hand, import receptors bind cytoplasmic cargo in 
the absence of RanGTP and release cargo upon binding to RanGTP in the nucleus. The 
RanGTP/import receptor complex is recycled back to the cytoplasm where RanGTP is 
again hydrolyzed to RanGDP. 
The classical NLSs, or basic type NLSs, are monopartite or bipartite clusters of 
basic amino acids (200). Nuclear import of proteins containing the basic type NLSs 
requires a nuclear pore targeting complex composed of importin a and importin 3 (73, 
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141). The NLS is recognized and bound by the importin a adaptor protein (51). The 
importin P receptor transports the NLS-containing cargo protein/importin a complex into 
the nucleus (50, 72). Other types of NLSs have been identified with no known homology 
to the basic type NLS (200). The most well characterized NESs are the leucine-rich 
NESs which are rich in hydrophobic amino acids and require leucine residues for 
function (200). The leucine-rich NESs are recognized and bound by the CRM1 receptor 
and are transported to the cytoplasm by CRM1 in complex with RanGTP (46, 47,170). 
In the absence of other viral proteins, pM141 is predominantly localized diffusely 
throughout the cytoplasm with significantly less nuclear staining and pM140 is localized 
almost entirely to the nucleus (82). Interestingly, when the proteins are co-expressed the 
localization of either protein is altered and they can be found co-localized in a perinuclear 
region with a punctate staining pattern (82). Thus, pM141 may retrieve pM140 from the 
nucleus. The complex localization pattern of the proteins suggests that the proteins may 
function in multiple subcellular locations and that proper regulation of localization may 
be required for function. As a prerequisite for understanding to what extent proper 
localization affects protein function we sought to map the localization domains of 
pM141. We hypothesized that pM141 can traverse the nuclear compartment and contains 
distinct signals for nuclear export and import since pM141 can be isolated from both 
compartments (61), may retrieve pM140 from the nucleus to the perinuclear locale, and 
since only pM141 is predicted to contain a NLS. Our approach to mapping the NES and 
NLS was to systematically cover the M141 gene with 5' or 3' deletions of increasing 
size. Then the localization of each mutated gene product, expressed transiently as an 
epitope tagged fusion, was assessed by immunofluorescence with confocal microscopy. 
76 
Mapping the localization domains would allow us to eventually generate mutant MCMV 
with altered trafficking of pM141, thus providing a means to assess this function in 
MCMV pathogenesis. 
Materials and Methods 
Generation of plasmids. We generated plasmid constructs designed to express 
either full-length or N- or C-terminally truncated pM141 proteins in transiently 
transfected cells. A construct that expresses full-length pM141 as a FLAG-epitope N-
terminal fusion protein under control of a mammalian expression promoter, FLAG-
M141, was generated as previously described (82). To generate N-terminal truncation 
mutants, distinct regions of the M141 gene were amplified by PCR using the primer pairs 
shown in Table 3 with FLAG-M141 (82) as template. The amplified products were 
ligated into pCR4-TOPO as an intermediate vector according to manufacturer's 
instructions and the M141 gene sequence was verified. The truncated M141 gene 
products were digested out of the intermediate vector using the Hindin and BamHI sites 
introduced by the primer sets (see Table 1 for the sites introduced) and the fragments 
were resolved by electrophoresis on a 1% agarose gel. Each fragment was purified using 
the QIAquick Gel Extraction Kit (Qiagen) according to manufacturer's instructions and 
was ligated into Hindin/BamHI-digested pEGFP-C3 (BD Biosciences) so that each 
mutant was expressed as a fusion protein with an N-terminal EGFP epitope tag. The 
resulting GFP141ForUSMl, GFP141ForUSM2, GFP141ForDSM3, and 
GFP141ForUSM4 constructs express pM141 deleted of 39, 62, 162, and 243 amino 
acids, respectively. A construct designed to express full-length pM141 with an N-
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terminal EGFP tag, GFP141FL, was also generated. A Sail to Smal fragment of FLAG-
M141 (82) was resolved on a 1% agarose gel, purifed with the Qiaquick Gel Extraction 
Kit according to manufacturer's instructions, and then ligated into Sall/Smal-digested 
pEGFP-Cl (BD Biosciences). 
TABLE 3. Primer pairs used to generate 5' truncations of M141 in the pCR4-TOPO background. 
Contents include the primer set (see Table 1) used to generate the plasmids listed in the Table and the full' 




















Constructs to express pM141 C-terminal mutants in transiently transfected cells 
were generated by subcloning the C-terminal truncation mutants from the pCR4-TOPO 
background (see Chapter HI) into p3XFLAG-CMV-7 (Sigma). Hindin to Bamffl 
fragments from 141MostCTerm/TOPO, 141NextCTerm/TOPO, 141DSM4/TOPO, 
141USNLS/TOPO, or 141USM4/TOPO were resolved on 1% agarose gels by 
electrophoresis and the DNA inserts were purified according to manufacturer's directions 
using the Qiaquick Gel Extraction Kit. Each purified fragment was subsequently ligated 
into Hmdin/BamHI-digested p3XFLAG-CMV-7 generating constructs, 
141MostCTerm/FLAG7, 141NextCTerm/FLAG7, 141DSM4/FLAG7, 
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141USNLS/FLAG7, and 141USM4/FLAG7, that express pM141 fused N-terminally 
with the FLAG epitope tag and deleted of 59, 115, 176, 202, and 251 N-terminal amino 
acids, respectively. 
We also generated plasmid constructs of the M141 gene that express C-terminally 
truncated proteins fused at the N terminus with the EGFP tag. The 
141MostCTerm/FLAG7, 141NextCTerm/FLAG7, 141DSM4/FLAG7, 
141USNLS/FLAG7, and 141USM4/FLAG7 plasmids were digested Hindffl to Bamffl 
and each purifed fragment was ligated into pEGFP-C3. Each mutant, 
GFPHlMostCTerm, GFPMlNextCTerm, GFP141DSM4, GFP141USNLS, and 
GFP141USM4 expresses pM141 deleted of 59, 115, 176, 202, or 251 amino acids, 
respectively. 
Restriction Enzyme Digestion. All restriction enzymes (New England Biolabs) 
were used according to manufacturer's directions. Typically, between 5-15 units of 
enzyme per ug of DNA was used in digestions which were reacted at the appropriate 
temperature for 3 to 5 hours. 
Ligations. Except where PCR products were ligated into the pCR4-TOPO vector 
using the TOPO TA Cloning Kit as per directed by the manufacturer, ligations were 
conducted using a minimum of a three fold molar ratio of insert to vector in the presence 
of 0.5 units of T4 DNA ligase (Invitrogen) according to the manufacturer's instructions 
with an overnight incubation at 4°C. 
Transformations. All transformations were performed with chemically-
competent cells as described. All transformations involving the pCR4-TOPO vector were 
performed in TOP 10 cells using the TOPO TA Cloning Kit for sequencing as per 
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manufacturer's instructions. All of the 5' M141 truncation mutants and the FLAG 
epitope fused C-terminal Ml 41 mutants were transformed into XL-1 blue cells with 1 to 
2 ul of DNA after a 30 minute incubation on ice. The transformation was performed with 
a heat shock at 42°C for 1.5 minutes. After an incubation on ice for 2 more minutes 
800ul of SOC Medium (153) was added to cells for a 1 hour recovery at 37°C with 
agitation. Competent cells were prepared as per Sambrook (153). GFP141FLwas 
transformed into NovaBlue cells (Novagen) according to manufacturer's instructions. 
All of the EGFP fused 3' M141 truncation mutants were transformed into TOP10 
cells with at least 1.5 ul of ligated DNA after a 30 minute incubation on ice. The 
transformation was performed with a heat shock at 42°C for 1 minute. After a 3 minute 
incubation on ice 1 ml of LB was added to cells for a 1 hour recovery at 37°C with 
agitation. Competent cells were prepared as per Sambrook (153). 
Polymerase chain reaction. PCR reactions were carried out with 20 pmol of 
forward and reverse primers and with 1 ng of template DNA using the Titanium Taq PCR 
Kit (Clontech) as per manufacturer's instructions except that 0.5 ul of DNA polymerase 
was used. Standard cycling conditions were as follows: 1 cycle of 95°C for 5 minutes; 
35 cycles of 95°C for 30 seconds, 65°C for 30 seconds, 72°C for 2.5 minutes; and 1 cycle 
of 72°C for 10 minutes on the MyCycler Thermal Gradient. 
Amplification of plasmids. When plasmids were required for the purpose of 
screening cloned DNA by restriction enzyme digestion the plasmids were amplified by 
growing a single colony of transformed bacteria (see above) overnight at 37°C with 
agitation in 3 ml of LB containing either 0.2 mg/ml ampicillin or 50 ug/ml kanamycin 
where appropriate. Approximately 1.5 ml of overnight culture was pelleted by 
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centrifugation at 14,000X g for 1 minute after which the resulting pellet was resuspended 
in 100 M! of Solution I (50 mM Tris, pH 8.0, 50 mM glucose, 10 mM EDTA). After a 5 
minute incubation on ice 200 uJ of Solution n (0.2 M sodium hydroxide, 1% Trition X-
100) was added to the sample. Cell lysis was allowed to proceed on ice until the cloudy 
solution began to clear (approximately 2-3 minutes). The solutions were neutralized by 
addition of 150 p.1 of Solution HI (3 M sodium acetate, pH 4.8). After a 5 minute 
incubation on ice the solutions were centrifuged for 5 minutes at 14,000X g. Supernatant 
was collected and incubated with 1 volume of isopropanol for 5-10 minutes at room 
temperature. Plasmids were harvested by centrifugation at 14,000X g for 5-10 minutes. 
The plasmid-containing pellet was washed with 500 ml of 70% ethanol and pelleted as 
before. The dried pellet was resuspended in 50 uJ of sterile water and then 10 ul was 
used per restriction digest. 
To generate large scale plasmid preparations the plasmids were first amplified in 
5 ml of starter culture of LB with 0.2 mg/ml ampicillin or 50 ug/ml kanamycin (where 
appropriate) overnight at 37°C with agitation. The starter culture was used to inoculate 
250 ml of LB containing the appropriate antibiotic which was incubated at 37°C with 
agitation for between 14-18 hours. Plasmids were purified using the Plasmid Maxi Kit 
(Qiagen) according to manufacturer's instructions. In some cases the Quantum Prep 
Plasmid Maxiprep Kit (Bio-Rad) was used to purify DNA. 
Sequencing. Sequencing reactions were performed using the BigDye Terminator 
v3.1 Cycle Sequencing Kit according to manufacturer's instructions except that the ready 
reaction premix was diluted 1:16 before use. Reactions were conducted using 1 pmol of 
Ml3 Forward or Reverse primers contained in the TOPO TA Cloning Kit (Ml3 primer 
sites flank the multiple cloning site of the vector) and, in some cases, the 
141RevDownstreamMotif4, 141RevMostCTerm, and 141Rev28fromTAG primers (Table 
1). In some cases the thermocycling conditions were as follows: 95°C for 30 seconds, 
47° for 10 seconds, and 60°C for 4 minutes for 34 cycles on a MyCycler Thermal Cycler. 
In other cases the following conditions were used to obtain longer sequence reads: 15 
cycles of 95°C for 10 seconds, 47°C for 5 seconds, 60°C for 1 minute and 15 seconds; 5 
cycles at 95°C for 10 seconds, 47°C for 5 seconds, 60°C for 1 minutes and 30 seconds; 5 
cycles at 95°C for 10 seconds, 47°C for 5 seconds, 60°C for 2 minutes. Sequencing was 
performed on an ABI Prism 3130 Genetic Analyzer from Applied Biosystems. 
Cells. NIH3T3 cells (CRL-1658; American Type Culture Collection), a mouse 
fibroblast line, were propagated in Dulbecco's Modified Eagle's Media (Mediatech) 
supplemented with 1% L-glutamine (Mediatech) and 10% heat-inactivated bovine calf 
serum (HyClone, Logan, UT). NTH3T3 cells were maintained in a humidified incubator 
at 37°C with 5% carbon dioxide. 
Transient Transfections. NIH3T3 cells were transfected using either 
TransFectin (Bio-Rad) or Metafectene (Biontex, Germany). When transfections were 
performed using Transfectin, cells were seeded into 25 cm2 culture flasks 24 hours prior 
at a density of 6 x 105 cells in 4 mis of propagation media. Cells were transfected with a 
total of 18 ul of Transfectin and a total of 9 ug of plasmid DNA. Plasmid DNA and 
Transfectin were added to 500 ul aliquots of Dulbecco's Modified Eagle's Media, mixed 
together, vortexed for 5 seconds, incubated at room temperature for 20 minutes, and 
added directly to the cells. Twenty four hours post-transfection approximately 1 x 105 
cells/4.2cm2 well were propagated into Two-Well Lab-Tek Chamber Slides (Nalge Nunc 
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International, Rochester, NY) which were processed 48 hours later. 
When using Metafectene, cells were seeded 18 hrs prior to transfection in 25 cm2 
culture flasks at a density of 3 x 105 cells. Six micrograms of plasmid DNA and 9 ul of 
Metafectene were added to 100 ul aliquots of Dulbecco's Modified Eagle's Media, mixed 
together, vortexed for 5 seconds, and incubated at room temperature for 20 minutes. 
Media used to seed the cells was removed, two milliliters of propagation media was 
added to the transfection mixes, and this was added to the cells. Twenty four hours post-
transfection approximately 1 x 105 cells/4.2cm2 well were propagated into Two-Well 
Lab-Tek Chamber Slides which were processed 48 hours later. 
Confocal microscopy. Cells propagated in chambered slides were washed three 
times in 1 ml of cold phosphate-buffered saline. Cells were fixed and permeablized by 
adding 1 ml of cold 100% methanol for a 10 minute incubation at -20°C after which the 
cells were washed three more times in phosphate-buffered saline. Cells were blocked in 
phosphate-buffered saline with 5% Sterile Goat Serum (Rockland Immunochemicals Inc., 
Gilbertsville, PA) (blocking solution) for 45 minutes at 37°C. Primary antibodies were 
diluted in blocking solution and applied for 45 minutes at 37°C. After three washes in 
phosphate-buffered saline, secondary antibody was diluted in blocking solution and 
incubated with the cells for 45 minutes at 37°C. Cells were washed again as before and 
in some cases the DNA-binding dye, TO-PRO-3 (Invitrogen), was diluted in blocking 
solution before adding to the cells for a 20 minute incubation at 37°C. After a final wash 
in phosphate-buffered saline, chambers were removed and approximately 10 ul of 
Component A from the SlowFade Antifade Kit (Invitrogen) was applied before adding 
glass coverslips. A Zeiss LSM510 laser scanning confocal microscope (Jena, Germany) 
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equipped with argon (488nm), HeNel (543nm), and HeNe2 (633nm) lasers was utilized 
for visualizing fluorescently-labeled cells and image analysis was performed using 
MetaMorph Offline 6.3 Meta Imagining Software (Molecular Devices Corporation, 
Sunnyvale, CA). 
Antibodies and Dyes. The following primary antibodies were used: Anti-
FLAG M2 monoclonal antibody (Sigma) and mouse IgGlK (Sigma) at 20 ug/ml or 
monoclonal anti-a-tubulin (Sigma) and mouse IgGlK (Sigma) at 1 ug/ml. Secondary 
antibodies were either whole molecule goat anti-mouse IgG TRITC Conjugate (Sigma) 
diluted 1:128 or Fc specific goat anti-mouse IgG FITC Conjugate (Sigma) diluted 1:200. 
When the nucleic acid stain TO-PRO-3 (Invitrogen) was used, the dye was diluted 
1:1000. 
Results 
The MHO and M141 proteins exhibit an altered localization depending on 
whether the proteins are co-expressed or expressed individually suggesting that the 
proteins may function in more than one subcellular location. As a prerequisite to 
understand the extent to which proper localization affects the function of the proteins we 
sought to map the interaction domain of pM141. For this purpose we generated 5' or 3' 
truncations in the M141 gene so that we could examine the localization of the truncated 
protein products. M141 is a member of the US22 gene family and contains all four 
conserved motifs characteristic of the family (Fig. 3) (21, 39, 59, 94, 119, 120, 143). The 
function of the motifs has not been identified. However, the conserved nature of the 
motifs suggests that they confer an important property to the proteins. Therefore, 
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identical to our approach for mapping interaction domains, we targeted the motifs in our 
deletion mapping. Additionally, we targeted the putative NLS of the protein. The N-
terminal truncation mutants are expressed as EGFP fusion proteins with an N-terminal 
tag (Fig. 19). The pGFPHlForUSMl mutant retains all four motifs and is deleted of 39 
N-terminal amino acids adjacent to Motif I. The pGFP141ForUSM2 mutant, missing 62 
N-terminal amino acids, is deleted of Motif I. The pGFP141ForDSM3 mutant is deleted 
of Motif II and III and is missing 162 amino acids at the N terminus. The 
pGFP141ForUSM4 mutant is deleted of 243 N-terminal amino acids adjacent to Motif 
IV. 
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FIG. 19. Map of the panel of pM141 N-terminal deletion mutants analyzed for localization domain 
mapping. Full-length pM141 is shown at the top along with the location of the US22 Motifs (open boxes), 
the putative NLS (hatched box) which shares some overlap with Motif IV, and the PEST motif (white box). 
The ruler is shown for reference with each tick mark corresponding to 10 amino acids. Each pM141 
deletion mutant is shown drawn to scale with the location of the GFP tag (not drawn to scale). 
85 
For these experiments we transiently-transfected fibroblast cells with plasmid 
constructs that express each of the deletion mutants or a construct expressing a full-length 
M141/EGFP fusion, GFP141FL. The EGFP tag in each protein was visualized directly 
by confocal microscopy. The nuclear compartment was delineated using TO-PRO-3 
while the cytoplasmic compartment was stained for oc-tubulin. We found that each of the 
N-terminal deletion mutants exhibited a localization pattern identical to that of the full-
length protein (Fig. 20) suggesting that the N terminus of the protein does not contain a 
localization domain. 
FL ForUSMI ForUSM2 
ForDMSS ForUSM4 
FIG. 20. Localization of the EGFP-tagged pM141 N-tenninal deletion mutants. NIH3T3 fibroblast cells 
were transfected with GFP141FL (FL), GFP141ForUSMl (ForUSMI), GFP141ForUSM2 (ForUSM2), 
GFP141ForDSM3 (ForDSNB), or GFP141ForUSM4 (ForUSM4). Approximately 72 hours post-
transfection the cells were stained to detect either the nucleus (TO-PRO-3; blue) or cytoplasm (anti-a-
tubulin primary and TRTTC-conjugated secondary; red). The M141 protein was detected via the EGFP tag 
shown in green. Confocal images are shown with an original magnification of x40. 
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Therefore, we similarly screened the panel of C-terminal deletion mutants except 
that these mutants contained an N-terminal FLAG epitope tag (Fig. 21). The 
pl41MostCTerm/FLAG7 and pl41NextCTerm/FLAG7 mutants retain all four US22 
Motifs and are deleted of 59 and 115 amino acids, respectively. The pl41DSM4/FLAG7 
mutant is deleted of 176 amino acids adjacent to the putative NLS. The 
pl41USNLS/FLAG7 mutant is deleted of the putative NLS and 202 C-terminal amino 
acids. The pl41USM4/FLAG7 mutant, deleted of the NLS and Motif IV, is missing 251 
amino acids. Fibroblasts were transiently-transfected with each of the mutant constructs 
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FIG. 21. Map of the panel of pM141 C-terminal deletion mutants analyzed for localization domain 
mapping. Full-length pM141 is shown at the top along with the location of the US22 Motifs (open boxes), 
the putative NLS (hatched box) which has some overlap with Motif IV, and the PEST motif (white box). 
The ruler is shown for reference with each tick mark corresponding to 10 amino acids. Each pM141 
deletion mutant is shown drawn to scale with the location of the FLAG epitope tag (not drawn to scale). 
87 
and pM141 was detected via staining for the FLAG epitope tag. Cells were 
counterstained with TO-PRO-3. We found that pl41MostCTerm/FLAG7 and 
pl41NextCTerm/FLAG7 displayed a localization identical to the full-length pM141 (Fig. 
22). However, pl41DSM4/FLAG7, pl41USNLS/FLAG7, and pl41USM4/FLAG7 
displayed an alternative localization. Some cells had a localization similar to the full-
length protein (not shown), but we observed significantly more nuclear staining in over 
half of the cells examined (Fig. 22). 
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FIG. 22. Localization of FLAG epitope tagged pM141 C-terminal deletion mutants. NIH3T3 fibroblasts 
cells were transfected with either FLAG-M141 (FL), 141MostCTerm/FLAG7 (MostCT), 
141NextCTerm/FLAG7 (NextCT), 141DSM4/FLAG7 (DSM4), 141USNLS/FLAG7 (USNLS), or 
141USM4/FLAG7 (USM4). Approximately 72 hours post-transfection the cells were stained with anti-
FLAG primary antibody and secondary antibody conjugated to TRTTC (red). Nuclei were stained with TO-
PRO-3 (blue). Shown are confocal microscopy images with an original magnification of x40. 
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We considered that the mutants displaying significantly more nuclear protein may 
be small enough to traverse the nucleus by passive diffusion. Therefore, each of the 
mutants was subcloned into a plasmid vector that confers expression as N-terminal EGFP 
fusion proteins, adding an additional 29 kDa to each of the mutant proteins. We found 
that the localization pattern was shifted (Fig. 23). As with the FLAG epitope tagged 
mutants, pGFP141MostCTerm and pGFP141NextCTerm had a localization pattern 
identical to full-length pM141. However, pGFP141DSM4 mutant also exhibited 
localization like full-length pM141 while the FLAG-tagged version of this mutant was 
observed to have significantly more nuclear protein (Fig. 22). Furthermore, although we 
observed that pGFP141USNLS and pGFP141USM4 have more nuclear protein compared 
to full-length protein (Fig. 23), we observed less accumulation compared to the FLAG-
tagged mutant proteins (Fig. 22) and only a fourth of the cells examined exhibited nuclear 
accumulation. These results suggest that the FLAG-tagged pl41DSM4, pl41USNLS, 
and pl41USM4 traversed the nucleus by passive diffusion. 
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FIG. 23. Localization ofEGFP-taggedpM141C-terminal mutants. NIH3T3 fibroblasts were 
transfected with either GFP141MostCTerm (MostCT), GFP141NextCTerm (NextCT), GFP141DSM4 
(DSM4), GFP141USNLS (USNLS), GFP141USM4 (USM4), or GFP141FL (FL). Cells were fixed and 
stained approximately 72 hours later with an anti-a-tubulin primary antibody and TRITC-conjugated (red) 
secondary antibody. Nuclei were stained with TO-PRO-3 dye (blue) and pM141 was detected via the 
EGFP tag (green). Confocal microscopy images are shown. Original magnification is x40. 
Discussion 
The M141 protein can be found in both cytoplasm (predominantly) and nucleus of 
infected cells while pM140 is localized mainly to the nucleus (82). However, when the 
proteins are co-expressed they co-localize to a perinuclear region (82). These results 
suggest that the proteins may function in multiple locations inside the cell. We 
hypothesized that pM141 contained a NES and NLS and sought to map the localization 
domains of the proteins as a prerequisite to better understand how proper localization is 
related to the function of the proteins. However, we were unable to detect either signal 
despite using a strategy that included deletion mapping with complete gene coverage. 
90 
Two main possibilities exist to explain our results: 1) the protein does contain signals for 
nuclear shuttling that were not uncovered by our strategy, or 2) the protein enters the 
nucleus via passive diffusion, but is shuttled back to the cytoplasm by a NES. 
Hypothesis: pM141 contains signals for nuclear shuttling not uncovered by 
our strategy. One strategy for mapping localization domains is to generate mutant 
proteins deleted of increasing N- and C-terminal amino acids (99, 125, 158). Using this 
strategy a localization domain is mapped by a process of elimination whereby a small 
deletion mutant retains localization like full-length protein and a mutant deleted of 
adjacent larger amino acids is excluded from a subcellular compartment of interest. We 
chose this strategy beacause of the availability of large scale deletion mutants already 
generated to map interaction domains of pM141 (see Chapter III) and because of the 
large size of the protein (509 amino acids). 
The fact that pM141 localizes predominantly to the cytoplasm is a complicating 
factor for this strategy. Proteins are translated in the cytoplasm and will remain there 
unless they are small enough to enter the nucleus by passive diffusion or if they contain 
localization signals for subcellular targeting (137,139, 168). It is possible that pM141 
contains a NLS and is retained in the cytoplasm by complexing with a protein that masks 
the NLS. In this case, if one of our deletion mutants is missing the NLS, regardless of 
whether the mutant has a NES, we would expect to see localization similar to the full-
length protein. 
The deletion mutant strategy is also complicated by the fact that the mutant 
proteins, upon further and further deletion of N- or C-terminal amino acids, can reach a 
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size small enough to diffuse passively through the nucleus. Although most nuclear transit 
is regulated and efficient localization requires nucleocytoplasmic shuttling, proteins up to 
60 kDa or more can enter the nucleus through passive diffusion (102, 137, 168, 190). 
The results from our localization mapping imply that we achieved passive diffusion of 
some of our smaller C-terminal deletion mutants. Some of our deletion mutants are small 
enough to conceivably diffuse into the nucleus passively. Two of our C-terminal deletion 
mutants, pl41MostCT and pl41NextCT, localized in a similar pattern to the full-length 
protein regardless of whether the proteins were fused to a FLAG or EGFP tag. The two 
smallest C-terminal mutants, pl41USNLS and pl41USM4, had a fairly equal distribution 
in the cytoplasm and nucleus, regardless of epitope tagging. However the pl41DSM4 
mutant displayed a localization pattern dependent on the size of the epitope tag. FLAG-
tagged pl41DSM4 exhibited an equal distribution between cytoplasm and nucleus similar 
to pl41USNLS and pl41USM4, while the EGFP-tagged mutant exhibited localization 
like the full-length protein. The FLAG tag is a small tag and only adds approximately 3 
kDa to the molecular weight of pM141. However, EGFP, a 29 kDa protein, has a 
considerably larger molecular weight. Our results indicate that the three smallest FLAG-
tagged mutants can diffuse passively into the nucleus and that addition of the EGFP tag 
to the pl41DMS4 mutant increases the size such that the protein cannot diffuse into the 
nucleus. Apparently, pl41USNLS and pl41USM4 remain small enough for passive 
diffusion even with the addition of EGFP. 
Another complication of a deletion strategy is the fact the protein of interest as a 
whole remains relatively intact and may thus retain an ability to bind to regulatory 
proteins. It is well documented that complexing between proteins can mask NES or NLS 
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and that this binding is a means of regulating the NES/NLS-containing protein (76, 137, 
139, 168). The interaction domains may also be deleted or affected leading to difficulty 
in interpreting results. Alternatively, a localization domain may be removed, but the 
protein is retained in a subcellular location because it retains an ability to bind to a 
regulatory protein. 
An alternative strategy for mapping NES/NLS is to break the protein up into 
small components which can passively enter the nucleus and which are then expressed 
fused to a protein, for example GFP, that does not contain localization signals and 
because of its size is diffusely distributed throughout the cell (42, 121, 186). Using this 
strategy the localization of each protein fragment is compared to that of GFP. If a 
fragment contains a localization signal then GFP will be relocalized to a distinct 
subcellular compartment. Future studies of pM141 localization should include this 
strategy for several reasons. First, although pM141 can be isolated from the nucleus, the 
majority of pM141 is localized to the cytoplasm (61, 82). Thus, if pM141 does contain a 
NLS/NES then the protein localization must be highly regulated. However, using the 
strategy with the GFP fusions the target protein does not remain intact and therefore the 
possibility that regulatory proteins can still bind is decreased. Furthermore, with this 
strategy results are interpreted on the basis of a protein fragment containing a signal 
rather than lacking one. Thus, each protein will localize to a subcellular compartment 
only if the fragment has a signal. This strategy also escapes the problem of passive 
diffusion of smaller deletion mutants as long as the protein fragments are designed to be 
small enough to passively enter the nucleus. Under these circumstances each mutant will 
localize diffusely throughout the cell with a pattern identical to GFP unless the protein 
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fragment contains a signal. 
Hypothesis: pM 141 contains a NES and enters the nucleus by passive 
diffusion. We hypothesized that pM141 contains a NES and NLS. Our hypothesis was 
based on several pieces of evidence: 1) when expressed individually pM141 localizes 
predominantly to the cytoplasm and to a lesser extent the nucleus while pM140 is almost 
entirely nuclear localized, 2) in the presence of pM141, pM140 is relocalized from the 
nucleus and co-localizes to a distinct perinucleur region with pM141, 3) bioinformatics 
analysis of pM141 revealed a putative NLS, while a NES was not predicted for pM141 or 
pM140 and 4) the proteins form a complex. An alternate hypothesis might be that 
pM140 is prevented from entering the nucleus by complexing with pM141 in the 
cytoplasm and that pM141 can enter the nucleus by passive diffusion, but is rapidly 
transported out of the nucleus by a NES. 
In support of our alternate hypothesis we have demonstrated that the proteins are 
coordinately regulated at the transcriptional and translation^ levels (59, 61). If pM140 is 
required in the nucleus at distinct times after infection or in response to specific cellular 
stimuli then the proteins would need to be coordinately expressed so that they could 
complex immediately post-translation and remain complexed until pM140 is required in 
the nucleus. Upon reception of a signal, pM140 would be released from pM141, 
exposing the NLS, and allowing pM140 to transit the nucleus. It is intriguing that pM141 
from infected cells is more rapidly degraded in the absence of pM140 (61). M141 protein 
levels are dependent on the concentration of pM140, but pM141 can be rapidly degraded 
even when the proteins retain an ability to form a complex (Chapter V). This further 
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demonstrates the complex interplay between the two proteins. It is tempting to speculate 
that pM141 retains pM140 in the cytoplasm until a signal is received causing the rapid 




REGULATION OF pM141 DEGRADATION BY pM140 
Introduction 
The proteasomes are the main intracellular proteolytic machinery and are 
responsible for proper functioning of cellular processes through regulated degradation of 
proteins (77). The proteasome is a large, multisubunit complex that is cylindrical in 
shape and lined with proteases that mediate degradation of targeted proteins (77). The 
most well characterized form of targeting proteins to the proteasome is by addition of 
polyubiquitin chains that are recognized by proteasomal components (77). Ubiquitin-
independent degradation of proteins is also observed, but is less well characterized 
currently (77). Several degradation signals have been identified. For example, PEST 
domains are commonly found on rapidly-degraded proteins in general and have 
commonly been observed on proteins degraded in a ubiquitin-dependent and proteasome-
dependent fashion (144). 
We previously observed that steady-state levels of pM141 were significantly 
reduced in the absence of pM140 and found that the protein exhibits an increased rate of 
turnover in the absence of pM140 relative to that in the presence of pM140 (61). 
Furthermore, analysis of the protein sequence of pM141 reveals a PEST domain. These 
results indicate that appropriate levels of pM141 may be important for the function of the 
protein. We hypothesized that pM141 is degraded by the ubiquitin-proteasome system. 
To address the question of whether degradation is proteasome-mediated we examined 
steady-state levels of pM141 in the presence or absence of pharmacological proteasome 
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inhibitors. To assess whether ubiquitin is required for degradation of pM141 we looked 
for ubiquitin-conjugates of the protein and assessed steady-state levels of the protein in 
an El ubiquitin ligase temperature-sensitive cell line. Given that pM141 is stabilized in 
the presence of pM140 and that the proteins form a stable complex (61, 82), we further 
hypothesized that direct complexing of the proteins was required for stabilization of 
pM141. Our approach was to determine if pM141 steady-state levels are dependent on 
the concentration of pM140. We also constructed M140 deletion mutants in order to map 
the region of pM140 required to stabilize pM141 and assessed whether these mutants 
retained an ability to complex with the protein. 
Materials and Methods 
Generation of plasmids. The pMT123 plasmid which expresses HA epitope 
tagged ubiquitin (184) was a kind gift from Lubbertus Mulder (The Rockefeller 
University, New York, NY). The pCS2m-cyclin E plasmid expressing a myc epitope 
tagged cyclin E protein (28), was a generous gift of David Pintel (University of Missouri-
Columbia, Columbia, MO). 
A plasmid designed to express full-length pM140 in with an N-terminal FLAG 
tag, FLAG140FL, was generated by first digesting Hisl40FL (82) with HindlH. The 
Hindlll site was subsequently blunted by reacting 1 unit of DNA Polymerase I, Large 
(Klenow) Fragment (New England Biolabs) per ug of linearized DNA with 0.05 mM 
dNTPs for 30 minutes at room temperature. The polymerase was heat inactivated at 75°C 
for 10 minutes before further digesting the vector with BamHI. Meanwhile p3XFLAG-
CMV-7 was digested with BamHI and Smal. The digested DNA was resolved by 
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electrophoresis on a 1% agarose gel. Vector and insert fragments were purified using the 
QIAquick Gel Extraction Kit according to manufacturer's instructions and ligations were 
performed as described below. 
For the purpose of mapping the domain of pM140 required to stabilize pM141 we 
generated plasmids designed to express pM140 C-terminal deletion fusion proteins with 
an N-terminal FLAG tag. FLAG140DSM3, FLAG140DSM4, and FLAG140USAcidic 
are deleted of 305, 179, or 105 amino acids, respectively. Each of the plasmids was 
generated by first digesting 140DSM3/TOPO, 140DSM4/TOPO, or 140USAcidic/TOPO 
with BamHI and Notl. Each fragment was ligated into BamHI/Notl-digested Hisl40FL 
generating 140DSM3/HisC, 140DSM4/HisC, and 140USAcidic/HisC. Then, 
BamHI/Apal-digested 140DSM3/HisC, 140DSM4/HisC, or 140USAcidic/HisC 
fragments were ligated into BamHI/Apal-digested FLAG140FL vector upon purification 
of DNA after electrophoresis as described above. 
A construct designed to express full-length pM141 as an N-terminally tagged 
FLAG epitope fusion protein under control of a mammalian expression promoter, FLAG-
M141, was generated as previously described (82). The pM141 plasmid (referred to as 
M141Nat in this work) which contains full-length M141 under control of the native gene 
promoter was generated by inserting a BamHI to Xbal fragment of pDJI (62) into 
Bgin/Xbal-digested pcDNA3 (Invitrogen). 
Restriction Enzyme Digestion. All restriction enzymes were used according to 
manufacturer's directions. Typically, between 5-15 units of enzyme per ug of DNA was 
used in digestions which were reacted at the appropriate temperature for 3 to 5 hours. 
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Ligations. Ligation reactions were conducted using a minimum of a three fold 
molar ratio of insert to vector in the presence of 0.5 units of T4 DNA Ligase according to 
the manufacturer's instructions with an overnight incubation at 4°C. 
Transformations. FLAG140DSM3, FLAG140DSM4, and FLAG140USAcidic 
plasmids were transformed into XL-1 blue cells with 1 to 2 ul of ligated DNA after a 30 
minute incubation on ice. The transformations were performed with a heat shock at 42°C 
for 1.5 minutes. After an incubation on ice for 2 more minutes 800ul of SOC Medium 
(153) was added to the cells for a 1 hour recovery at 37°C with agitation. Competent 
cells were prepared as per Sambrook (153). The pCS2m-cyclin E and pMT123 plasmids 
were transformed into XL-1 blue cells with 50-100 ng DNA. FLAG140FL was 
transformed into NovaBlue cells (Novagen) according to manufacturer's instructions. 
Amplification of plasmids. When plasmids were required for the purpose of 
screening cloned DNA by restriction enzyme digestion the plasmids were amplified by 
growing a single colony of transformed bacteria (see above) overnight at 37°C with 
agitation in 3 ml of Luria-Bertani Medium (LB) (153) containing either 0.2 mg/ml 
ampicillin (Sigma) or 50 ug/ml kanamycin (Sigma) where appropriate. Approximately 
1.5 ml of overnight culture was pelleted by centrifugation at 14,000X g for 1 minute after 
which the resulting pellet was resuspended in 100 ul of Solution I (50 mM Tris, pH 8.0, 
50 mM glucose, 10 mM EDTA). After a 5 minute incubation on ice 200 ul of Solution II 
(0.2 M sodium hydroxide, 1% Trition X-100) was added to the sample. Cell lysis was 
allowed to proceed on ice until the cloudy solution began to clear (approximately 2-3 
minutes). The solutions were neutralized by addition of 150 uJ of Solution HI (3 M 
sodium acetate, pH 4.8). After a 5 minute incubation on ice the solutions were 
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centrifuged for 5 minutes at 14.000X g. Supernatant was collected and incubated with 1 
volume of isopropanol for 5-10 minutes at room temperature. Plasmids were harvested 
by centrifugation at 14,000X g for 5-10 minutes. The plasmid-containing pellet was 
washed with 500 ml of 70% ethanol and pelleted as before. The dried pellet was 
resuspended in 50 ul of sterile water and then 10 ul was used per restriction digest. 
To generate large scale plasmid preparations the plasmids were first amplified in 
5 ml of starter culture of LB with 0.2 mg/ml ampicillin or 50 ug/ml kanamycin (where 
appropriate) overnight at 37°C with agitation. The starter culture was used to inoculate 
250 ml of LB containing the appropriate antibiotic which was incubated at 37°C with 
agitation for between 14-18 hours. Plasmids were purified using the Plasmid Maxi Kit 
(Qiagen) according to manufacturer's instructions. In some cases the Quantum Prep 
Plasmid Maxiprep Kit (Bio-Rad) was used to purify DNA. 
Cells. IC-21 cells (TIB-186; American Type Culture Collection, Manassas, VA), 
a mouse peritoneal macrophage line, were maintained in RPMI-1640 media (Mediatech 
Incorporated, Manassas, VA) supplemented with 1% L-glutamine and 10% heat-
inactivated fetal bovine serum. NIH3T3 cells (CRL-1658; American Type Culture 
Collection), a mouse fibroblast line, were propagated in Dulbecco's Modified Eagle's 
Media supplemented with 1% L-glutamine and 10% heat-inactivated bovine calf serum. 
IC-21 and NIH3T3 cells were maintained in a humidified incubator at 37°C with 5% 
carbon dioxide. The ts20 cells (a generous gift from Harvey Ozer, UMDNJ-New Jersey 
Medical School, Newark, NJ) were derived from mouse BALB/3T3 clone A31 fibroblast 
cells and were propagated in Dulbecco's Modified Eagle's Media (1% L-glutamine; 10% 
heat-inactivated bovine calf serum) in a humidified incubator at 37°C (except where 
indicated) with 5% carbon dioxide. 
Viruses. Wild type MCMV (VR-194; ATCC) utilized in these experiments is 
Smith strain. Construction of mutant viruses disrupted of expression of MHO (RVA140) 
or M141 (RVA141), or deleted of M139 and MHO (RV12) was previously described (61, 
82). Viruses were propagated in NIH3T3 cells and virus titers were determined by 
plaque assay as previously described (19). 
Transient transfections. NIH3T3 cells were transfected using either TransFectin 
or Metafectene. When transfections were performed using Transfectin, cells were seeded 
into 25 cm2 culture flasks 24 hours prior at a density of between 6-7 x 105 cells in 4 mis 
of propagation media. Cells were typically transfected with a total of 18 ul of 
Transfectin and a total of 9 ug of plasmid DNA, but in cases where less plasmid was used 
a 2:1 ratio of Transfectin volume to microgram of DNA was maintained. Plasmid DNA 
and Transfectin were added to 500 ul aliquots of Dulbecco's Modified Eagle's Media, 
mixed together, vortexed for 5 seconds, incubated at room temperature for 20 minutes, 
and added directly to the cells. Approximately 24 hours post-transfection cells were 
seeded onto 100 mm dishes which were harvested 48 hours later. In some cases the cells 
were infected 24 hours after seeding onto 100 mm dishes using 2 PFU/cell of virus in 2 
ml of media with rocking for 1 hour. Virus-containing media was removed, replaced 
with fresh propagation media, and cells were incubated between 16-20 hours prior to 
harvesting. 
When using Metafectene, cells were seeded 18 hours prior to transfection in 25 
cm2 culture flasks at a density of 3-4 x 105 cells. Six micrograms of plasmid DNA and 9 
ul of Metafectene were added to 100 ul aliquots of Dulbecco's Modified Eagle's Media, 
mixed together, yortexed for 5 seconds, and incubated at room temperature for 20 
minutes. Media used to seed the cells was removed, 2 mis of media was added to the 
transfection mixes, and this was added to the cells. Approximately 24 hours post-
transfection cells were seeded onto 100 mm dishes which were harvested 48 hours later. 
In some cases the cells were infected 24 hours after seeding onto 100 mm dishes using 2 
PFU/cell of virus in 2 ml of media with rocking for 1 hour. Virus-containing media was 
removed, replaced with fresh media, and cells were incubated between 16-20 hours prior 
to harvesting. 
Infections. Between 5-6.5 x 105 NTH3T3 cells, 1 x 106 IC-21 cells, or 6 x 105 
ts20 cells were seeded into 60 mm dishes. Approximately 24 hours later NIH3T3 and 
ts20 cells were infected with 2 PFU/cell of virus in 1 ml of media with rocking for 1 
hour. When infecting IC-21 cells, 4 PFU/cell of virus was used in 1 ml of media with 
rocking for 2 hours. After infection, virus-containing media was removed and fresh 
propagation media was added to the cells. Cells were harvested 16-20 hours later. 
Western blotting. NIH3T3, IC-21, and ts20 cells expressing proteins of interest 
or control proteins were harvested, counted, and normalized based on cell numbers prior 
to resuspension in western lysis buffer (50 mM Tris, pH 7.5, 1% SDS). Equal volumes of 
cell lysates were electrophoresed on 12.5% SDS-polyacrylamide gels after boiling in the 
presence of IX SDS loading dye. Transfer of proteins from the gel onto 0.45 
micrometer, supported, pure nitrocellulose (GE Water and Process Technologies, 
Trevose, PA) was conducted at 134 milliAmps for 1 hour and 50-60 minutes using a 
semi-dry electroblot apparatus. The gel and nitrocellulose membrane were layered 
between two pieces of Whatman 3MM CHR chromatography paper soaked in cathode 
buffer (25 mM Tris, pH 9.4, 40 mM 6-Aminohexanoic acid, 20% methanol) and two 
pieces of Whatman 3MM CHR chromatography paper soaked with either anode buffer #1 
(0.3 M Tris, pH 10.4, 20% methanol) (exposed to the anode) or anode buffer #2 (25 mM 
Tris, pH 10.4, 20% methanol) (exposed to the nitrocellulose also soaked with anode 
buffer #2). Post-transfer, membranes were blocked overnight in Tris-buffered saline 
(TBS; 10 mM Tris, pH 7.5, 0.15 M NaCl) with 5% Carnation powdered non-fat milk and 
0.1% Tween-20 (blocking solution). Membranes were probed for 1 hour in blocking 
solution using primary antibodies at the following concentrations: monoclonal anti-El 
(Ubiquitin Activating Enzyme) (Sigma) at 5 ug/ml, polyclonal anti-M140 or -M141 (61) 
diluted 1:500, and monoclonal anti-B-Actin at 0.3 ug/ml. Membranes were washed three 
times in TBS with 0.1% Tween-20 for at least 10 minutes each, probed with secondary 
antibodies in blocking solution for 1 hour, and washed again. Secondary antibodies 
conjugated to infrared fluorescent dyes were used for detection with the LI-COR 
(Lincoln, NE) Odyssey Infrared Imaging System. IRDye 680 Conjugated goat anti-
mouse IgG (LI-COR) was used at 1:20,000 and IRDye 800CW Conjugated goat anti-
rabbit IgG (LI-COR) at 1:15,000 according to manufacturer's directions. 
Immunoprecipitations. Immunoprecipitations were performed to detect 
complexing between pM141 and full-length or truncated pM140. NTH3T3 cells infected 
and/or transiently-transfected to express proteins of interest or control proteins were 
washed three times in phosphate-buffered saline, harvested in 1ml immunoprecipitation 
lysis buffer (50mM Tris [pH 7.5], 5mM EDTA, 150mM NaCl, 0.5% NP-40, 0.5% 
deoxycholate, ImM PMSF, 10 ug of aprotinin/ml) and clarified for cellular debris at 
14.000X g for 1 minute. One hundred microlitres of clarified lysate was retained as input 
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for SDS-PAGE. Immunoprecipitations were performed using 400-450 ul of clarified 
lysate and 5 ul of anti-M141 antibody or preimmune serum. Prior to 
immunoprecipitation all lysates were precleared with preimmune serum: 5 ul of 
preimmune serum was incubated with aliquots of lysate for 30 minutes at 4°C with 
rotation after which 60 ul Protein A-Agarose (Roche) was added and incubated for 1 
hour. After centrifugation at 10,000X g for 2 minutes the supernatant containing 
precleared lysates was removed for specific immunoprecipitations. Precleared lysates 
and anti-M141 or preimmune serum was incubated at 4°C with rotation. Twenty four 
hours later, 60 ul of protein A-agarose was added to the protein/antibody complexes for 
an additional incubation of 4 hours. Immune complexes were washed three times in 
SNNTE buffer and three times in RIPA buffer with centrifugations of 10,000X g at 4°C 
for 2 minutes between each wash. Protein complexes were denatured with 5 minutes of 
boiling in the presence of SDS-PAGE loading dye and 2 ul B-mercaptoethanol prior to 
SDS-PAGE on 12.5% acrylamide gels. Western blots were performed identical to those 
described above with 10 ug/ml of anti-FLAG M2 monoclonal antibody as the primary 
antibody. 
Immunoprecipitations were also performed to detect polyubiquitinated pM141 or 
myc epitope-tagged cyclin E as a positive control. Infected and/or transiently-transfected 
NIH3T3 cells expressing proteins of interest or control proteins were washed three times 
in phosphate-buffered saline, harvested in 1ml immunoprecipitation lysis buffer 
containing 5 mM N-ethylmaleimide (Sigma), and clarified for cellular debris at 14,000X 
g for 1 minute. One hundred microlitres of clarified lysate was retained as input for SDS-
PAGE. Immunoprecipitations were performed with a 2 hour incubation at 4°C using 
400-450 ul of clarified lysate and the following antibodies: 5 ul of anti-M141 antibody 
or preimmune serum and 0.4 ug of Myc-Tag monoclonal antibody (Cell Signaling 
Technology) or IgG2a mouse isotype control. Twenty four hours later, 60 ul of protein 
A-agarose was added to the protein/antibody complexes for an additional incubation of 4 
hours. Immune complexes were washed three times in SNNTE buffer and three times in 
RIP A buffer with centrifugations of 10,000X g at 4°C for 2 minutes between each wash. 
Protein complexes were denatured with 5 minutes of boiling in the presence of SDS-
PAGE loading dye and 2 ul J3-mercaptoethanol prior to SDS-PAGE on 12.5% acrylamide 
gels. Western blots were performed identical to those described above with 0.8 ug/ml of 
anti-HA monoclonal antibody (Roche). 
Inhibitors. All inhibitors were added to cells in propagation media and were 
used at the indicated concentrations according to manufacturers' instructions. 
Proteasome inhibitors, MG132 and epoxomicin, were purchased from Calbiochem 
(Gibbstown, NJ). The protein translation inhibitor, cycloheximide, was purchased from 
Sigma (Saint Louis, MI). 
Results 
Mechanism of pM141 Degradation. Our previous studies had indicated that the 
rate of pM141 degradation was enhanced in the absence of pM140 (61). As a 
prerequisite to understanding to what extent pM141 levels affect protein function, we 
wanted to determine the mechanism of pM141 degradation. Proteasome-mediated 
degradation is the most common method of proteolysis (27, 142) so we first asked 
whether pM141 would accumulate in the presence of the proteasome inhibitor, MG132. 
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Thus, IC-21 macrophages were infected with either WT virus or virus deleted of the 
MHO gene, RVA140 (61), and were then treated with MG132. We found that in the 
presence of pM140, pM141 levels accumulated to higher steady-state levels in the 
presence of drug treatment in a dose-dependent manner when compared to vehicle-
treated cells (Fig. 24A). The relative amount of pM141 expression was 1.4 fold higher in 
the presence of 25 uM MG132 than vehicle and 2.5 fold higher than vehicle when 75 uM 
MG132 was applied to the cells (Fig. 24B). In RVA140 infected cells that received 
treatment with vehicle only, pM141 is not detectable (Fig. 24) which correlates with the 
increased rate of pM141 turnover when pM140 is not present (61). However, when the 
RVA140 infected cells were treated with MG132, pM141 accumulated to detectable 
levels in a dose-dependent manner with a 3 fold increase from 25 to 75 uM MG132 (Fig. 
24). These results suggest that degradation of pM141 is proteasome-dependent. 
However, MG132 is a relatively non-specific proteasome inhibitor. We therefore used 
epoxomicin, which is among the most specific proteasome inhibitors (92), to confirm that 
pM141 is sensitive to degradation by the proteasome. As with MG132, pM141 from 
WT-infected cells accumulated in a dose-dependent manner in the presence of 
epoxomicin (Fig. 25). M141 protein levels were 1.2 fold higher in the presence of 5 uM 
epoxomicin compared to vehicle and 1.3 fold higher in the presence of 10 uM 
epoxomicin. As seen previously, levels of pM141 in the absence of pM140 were below 
the level of detection in the presence of vehicle alone while the levels were readily 
detectable in the presence of either 5 or 10 uM epoxomicin (Fig. 25). However, in 
RVA140-infected cells we did not observe a dose-dependent response of pM141 to 
epoxomicin as seen with MG132 (Fig. 25). It is possible that functionally saturating 
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FIG. 24. Steady-state levels of pM141 from infected IC-21 macrophage cells in the presence or absence 
of MG132. IC-21 macrophages were mock infected or infected with 4 PFU/cell of either WT or RVA140. 
Four hours post-infection the indicated amounts of MG132 or Vehicle (DMSO) were added to the cells for 
approximately 18 hours. Cells were harvested, counted, and normalized based on cell number prior to 
electrophoresis on a 12.5% acrylamide gel. A. Western blot analysis probing for pM141 (141) or Actin as 
a loading control. B. Quantitation of pM141 levels of WT- (left panel) or RVA140-(right panel) infected 
cells shown in relative units after values were normalized to levels of actin. 
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FIG. 25. Steady-state levels of pM141 from infected IC-21 macrophage cells in the presence or absence 
of epoxomicin. IC-21 macrophages were mock infected or infected with 4 PFU/cell of either WT or 
RVA140. Four hours post-infection the indicated amounts of epoxomicin (epoxi) or vehicle (DMSO) were 
added to the cells for approximately 18 hours. Cells were harvested, counted, and normalized based on cell 
number prior to electrophoresis on a 12.5% acrylamide gel. A. Western blot analysis probing for pM141 
(141) or Actin as a loading control. B. Quantitation of pM141 levels from WT- (left panel) or RVA140-
(right panel) infected cells are shown in relative units and after values were normalized to levels of actin. 
doses of epoxomicin were achieved at 5 uM in this cell type. Regardless, pM141 levels 
are higher in the presence of proteasome inhibitors in WT infected cells and pM141 
accumulates to detectable levels only in the presence of inhibitors in RVA140 infected 
cells. These results clearly indicate that degradation of pM141 in IC-21 macrophages is 
proteasome-dependent. 
Given that pM141 functions in macrophage tropism, we asked whether the 
regulation of pM141 through proteasomal degradation was cell type specific. Therefore, 
NTH3T3 fibroblasts were infected with WT or RVA14Q and then treated with proteasome 
inhibitors. Similar to the results in IC-21 macrophages, we observed an accumulation of 
pM141 from WT- or RVAl40-infected fibroblasts treated with either MG132 (Fig. 26A) 
or epoxomicin (Fig. 27 A) compared to that of vehicle-treated cells. M141 protein levels 
were 1.2 fold and 3.7 fold higher in WT-infected cells treated with 25 or 75 uM MG132, 
respectively, compared to vehicle-treated cells (Fig. 26B). In RVA140-infected cells 
pM141 was only detectable in the presence of MG132 and the accumulation was dose-
dependent exhibiting 1.9 fold higher levels in 75 uM versus 25 uM MG132. Although 
we did not observe a dose-dependent increase in pM141 from WT-infected fibroblasts 
treated with epoxomicin the protein accumulated to greater amounts in the presence of 
inhibitor relative to vehicle (1.8 fold increase with 1 uM epoxomicin and 1.2 fold 
increase with 5 uM) (Fig. 27B). As seen with MG132 treatment, epoxomicin treatment 
of RVA140-infected fibroblasts led to the accumulation of detectable pM141 in a dose-
dependent fashion with a 2.4 fold increase in the presence of 5 uM epoximicin compared 
to that of 1 uM inhibitor (Fig. 27B). These results demonstrate that proteasome-mediated 
degradation of pM141 is not cell type specific. 
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FIG. 26. Steady-state levels of pM141 from infected NIH3T3 fibroblast cells in the presence or absence 
ofMG132. Fibroblasts were mock infected or infected with 2 PFU/cell of either WT or RVA140. Four 
hours post-infection the indicated amounts of MG132 or vehicle (DMSO) were added to the cells for 
approximately 18 hours. Cells were harvested, counted, and normalized based on cell number prior to 
electrophoresis on a 12.5% acrylamide gel. A. Results from Western blot analysis probing for pM141 
(141) or Actin as a loading control. B. M141 protein levels were normalized to actin and the quantitation 
(shown in relative units) from each western blot is shown where WT-infected cells are represented in the 
left panels and RVA140-infected cells are represented in the right panels. 
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FIG. 27. Steady-state levels of pM141 from infected NIH3T3 fibroblast cells in the presence or absence 
of epoxomicin (epoxi). Fibroblasts were mock infected or infected with 2 PFU/cell of either WT or 
RVA140. Four hours post-infection the indicated amounts of epoxomicin or vehicle (DMSO) were added 
to the cells for approximately 18 hours. Cells were harvested, counted, and normalized based on cell 
number prior to electrophoresis on a 12.5% acrylamide gel. A. Results from Western blot analysis probing 
for pM141 (141) or Actin as a loading control are shown. B. M141 protein levels were normalized to actin 
and the quantitation (shown in relative units) from each western blot is shown where WT-infected cells are 
represented in the left panels and RVA140-infected cells are represented in the right panels. 
I l l 
Addition of polyubiquitin chains is the most well studied mechanism to target 
proteins to the proteasome for degradation. Thus, we were interested to see if pM141 
degradation is ubiquitin-dependent. In order to detect polyubiquitinated forms of pM141, 
we transfected WT- and RVA140-infected cells with a plasmid expressing a HA-tagged 
ubiquitin. The cell lysates were subsequently subjected to immunoprecipitation with 
anti-M141 antibody and then Western blots were performed with anti-HA to detect the 
HA-tagged ubiquitin molecules that would be incorporated into polyubiquitin chains. We 
could not detect polyubiquitinated forms of pM141 in infected cells even in the presence 
of MG132 (Fig. 28, top panel) although polyubiquitinated forms of the positive control 
protein, myc-tagged Cyclin E, were clearly detectable under identical conditions (Fig. 28, 
bottom panel, lane 4). 
To further investigate whether degradation of pM141 requires ubiquitin, we 
utilized the BALB/c 3T3-derived cell line, ts20, containing a temperature-sensitive defect 
in the El ubiquitin-activating enzyme (26, 204). At the permissive temperature of 35°C 
the enzyme is fully functional and proteins targeted for degradation are ubiquitinated. At 
the non-permissive temperature of 39°C the El enzyme is severely defective, ubiquitin 
tagging of proteins is compromised, and proteins that require ubiquitination for 
degradation accumulate. The feasibility of this approach was demonstrated using p53 as 
a positive control. As previously reported (26), p53 accumulated to high steady-state 
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levels in ts20 cells incubated at the non-permissive temperature, but not at 35°C when the 
El enzyme is functional (Fig. 29, middle panel). We examined pM141 expression in 
ts20 cells infected with either WT or RVA140 at the permissive and non-permissive 
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FIG. 28. Immunoprecipitation of pM141 or positive control protein from WT- or RVA140-infected cells 
expressing HA-tagged ubiquitin molecules (HA-Ub). NIH3T3 cells were transfected with HA-Ub alone 
(top panel) or in conjunction with a myc-epitope tagged Cyclin E construct (mycCycE). Approximately 
48hours later the transfected cells were infected with 2 PFU/cell of either WT or RVA140 (top panel) or 
were mock infected (bottom panel). MG132 or vehicle (DMSO) was added to the cells 4 hours post-
infection as indicated and the lysates were harvested approximately 18 hours post-treatment. Lysates were 
subjected to immunoprecipitations with anti-M141 or preimmune serum (preimm) in the top panel and with 
anti-myc or isotype-matched control antibody (IgG2a) in the bottom. Immune-precipitates were loaded on 
SDS-PAGE and western blot was performed with anti-HA antibody (top and bottom panels). 
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FIG. 29. Steady-state levels ofpM141 from WT- or RVA140- infected ts20 cells. The ts20 cells were 
either mock infected or infected with 2 PFU/cell of either WT or RVA140 after which cells were incubated 
at the permissive (35°) or non-permissive (39°) temperatures. After approximately 18 hours the cells were 
harvested, counted, and normalized based on cell number prior to electrophoresis. Top panel shows 
expression of pM141 (141) after Western blot analysis. The membrane was reprobed with antibodies 
against p53 (middle) as a positive control or actin (bottom) as a loading control. 
temperatures. M141 protein from WT-infected cells showed no evidence of 
accumulation at the non-permissive temperature (Fig. 29, top panel). Given the severe 
reduction of pM141 steady-state levels in RVAl40-infected fibroblasts and macrophages 
we were not surprised that pM141 was undetectable in the ts20 cells at the permissive 
temperature. Importantly, however, we were also unable to detect pM141 at the non-
permissive temperature in the absence of pM140. The inability to detect pM141 was not 
due to a defect in viral gene expression since RVA140 replicated to levels similar to WT 
in this cell line at either temperature (Table 4). The results from Fig. 28 and Fig. 29 
demonstrate that degradation of pM141 is ubiquitin-independent. 
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TABLE 4. WT and RVA140 titers in ts20 cells. The ts20 cells were infected at 35°C with 2 PFU/cell of 
the viruses shown. After infection cells were maintained at 35°C or shifted to 39°C for approximately 18 





9.5 x 103 PFU/ml 
5.5 x W PFU/ml 
39°C 
1.3 x 104 PFU/ml 
1.55 x 10j PFU/ml 
Mapping the degradation signal of pM141. We were also interested in 
mapping the degradation signal in pM141 in order to assist in defining the ubiquitin-
independent mechanism of pM141 degradation. Bioinformatics analysis of the protein 
using the PEST-FIND program (144, 149) revealed a sequence rich in proline, glutamic 
acid, serine, and threonine (PEST) located at the C- terminus of M141 (Fig. 3). The 
PEST hypothesis was proposed by Rogers et al (149) in support of the finding that PEST 
motifs are found in many proteins that undergo rapid turnover. We wanted to determine 
if the putative PEST motif was a functional degradation signal and if not, what region of 
the protein is required for degradation. These experiments required us to generate 
deletion mutants expressed from transient transfections for the purpose of comparing 
their rate of degradation to that of full-length pM141. Therefore, we wanted to test 
whether transiently-transfected pM141 had properties comparable to that of pM141 
expressed in the context of a virus infection. 
First, we sought to determine if transiently-transfected pM141 was degraded via 
the proteasome. For this purpose we treated cells with epoxomicin and assessed steady-
state levels of pM141 expressed transiently from a plasmid designed to expresses full-
length pM141 as a FLAG epitope tag, FLAG-MI41. Fibroblasts were transfected with 
FLAG-M141 and in some cases were then infected with either RVA141 or RVA140. 
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Cells were treated with epoxomicin or vehicle after which the steady-state levels of 
pM141 were compared. As expected, pM141 was not detectable when the cells were 
infected with RVA141 in the absence of FLAG-MI 41 expression, but pM141 
accumulated in the presence of epoxomicin relative to vehicle regardless of whether the 
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FIG. 30. Steady-state levels of pFLAG-M141 in the presence or absence of epoxomicin. NTH3T3 
fibroblasts were either mock infected or infected with 2 PFU/cell of the indicated viruses. Where indicated, 
the cells were transfected with the FLAG-M141 plasmid. Four hours post-infection the cells were treated 
with 1 uM epoxomicin for approximately 18 hours. Cells were harvested, counted, and normalized based 
on cell number prior to loading of lysates for SDS-PAGE. Western blot analysis was performed to detect 
pM141 (141) or actin. Location of the FLAG epitope-tagged pM141 (FLAG141), non-tagged pM141 
(141), and a non-specific band (NS) are shown. 
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pM141 and a higher molecular weight non-specific band as well. The specific band with 
a higher molecular weight corresponds to pM141 expressed as FLAG epitope fusion 
protein driven by the start codon upstream of the FLAG epitope sequence. The lower 
molecular weight pM141 band most likely corresponds to pM141 without the FLAG 
epitope expressed from the Ml 41 start codon that is still present in the gene after cloning. 
This is supported by the fact that the lower molecular weight band is the same size as 
pM141 from infected cells. Results from Fig. 30 demonstrate that degradation of 
transiently-expressed pM141 is proteasome-dependent and these results are consistent 
with the results from pM141 expressed endogenously from infected cells. 
We next asked if the half-life of transiently-expressed pM141 is comparable to 
that of pM141 expressed in infected cells. Therefore, we used cycloheximide to 
determine the turnover rate of transiently-expressed pFLAG-M141. Fibroblasts were 
transiently transfected with FLAG-M141, treated with cycloheximide, cell lysates were 
harvested at 2, 4, 6, and 8 hours post-treatment, and then Western blot analysis was 
performed. We found that pM141 expressed transiently from the FLAG-M141 construct 
was clearly detectable at each of the time points tested (Fig. 31 A) and had a half-life of 
approximately 4 hours (Fig. 3 IB) despite the absence of pM140 expression. This finding 
was surprising since pM141 from RVAl40-infected cells was below the limit of detection 
even at 1 hour post-cycloheximide treatment (data not shown). We considered the 
possibility that the stability of transfected pM141 would be altered in the presence of 
viral infection. We performed similar experiments with transfected FLAG-MI41 except 
that the cells expressing the construct were also infected with RVA140 so that we could 
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FIG. 31. Stability of transiently-expressed pFLAG-M141 from cycloheximide-treated cells. NIH3T3 
fibroblasts were either mock (M) transfected or were transfected with FLAG-M141. Approximately 72 
hours post-transfection the cells were treated with 100 ug/ml cycloheximide or vehicle (DMSO) and were 
harvested at the indicated times post-treatment. Prior to SDS-PAGE cells were counted and normalized to 
cell numbers. A. Western blot analysis to detect pM141 (141) or Actin which served as a loading control. 
B. Quantitation of pM141 Western blot shown in A after normalizing to Actin. Amount of pM141 is 
expressed as a percentage to the density of the protein before drug was added. 
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absence of pM140. As before, pM141 from RVA140-infected cells was clearly visible as 
long as 8 hours post-treatment (Fig. 3 2 A). However, the half-life of the protein was 
determined to be greater than 8 hours (Fig. 32B). Therefore, we are unable to map the 
degradation signal of pM141 by transiently expressing deletion mutants. 
Regulation of pM141 degradation by pM140. We had previously demonstrated 
the importance of pM140 expression on the stability of pM141 in infected cells (61) and 
we wanted to determine the extent to which pM141 stability was dependent on pM140. 
To answer this question NIH3T3 cells were transfected with increasing amounts of a 
plasmid that expressed full-length pM140 as a FLAG epitope fusion protein, 
FLAG140FL. The transfected cells were subsequently infected with RVA140 and the 
steady-state levels of pM141 were assessed by Western blot analysis of cell lysates. As 
shown in Fig. 33, pM141 stability was dependent on the concentration of pM140 
expressed in the infected cells. Steady-state levels of pM141 increased with increasing 
concentrations of FLAG140FL plasmid. Steady-state levels of pM141 were barely above 
the limit of detection in RVA140-infected cells when pFLAG140FL was not expressed 
(Fig. 33 A), but the relative amount of pM141 increased with increasing amount of M140 
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FIG. 32. Stability of pFLAG-M141 in RVA140-infected,cycloheximide-treated fibroblasts. NIH3T3 
fibroblasts were transfected with FLAG-M141 or were mock (M) transfected and then approximately 48 
hours post-transfection the cells were infected with 2 PFU/cell of RVA140. Eighteen hours later the cells 
were incubated with 100 ng/ml cycloheximide or vehicle (DMSO). Cell were harvested at the indicated 
times post-treatment by counting and normalizing to cell number. A. Western blot analysis of lysates from 
SDS-PAGE to detect either pM141 (top) or Actin as loading control (bottom). B. The relative amount of 
pM141 was normalized to actin and quantitated. M141 protein levels are shown as percent density relative 
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FIG. 33. Steady-state levels ofpM141 in the presence of increasing amounts of pFLAG140FL. NIH3T3 
fibroblasts were transfected with 0,1.13,2.25,4.50, or 9.00 \ig of FLAG140FL as indicated or were not 
transfected (Null). Approximately 48 hours later the transfected cells were infected with 2 PFU/cell of 
RVA140. Cells were harvested, counted, and normalized to cell number approximately 18 hours post-
infection. A. Western blot analysis was performed after SDS-PAGE of lysates. The blot was probed with 
antibodies to detect pM141 (top) or Actin (bottom) as a loading control after which the blot was reprobed 
with anti-M140 antibodies (middle). B. M141 protein levels were normalized to levels of Actin. The 
quantitation is displayed in relative units. 
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Several pieces of evidence lead us to hypothesize that direct complexing of 
pM140 with pM141 was responsible for the increased stability of pM141 in WT versus 
RVA140-infected cells. First, we have previously demonstrated that pM140 and pM141 
are found in complex with each other and in a larger complex (82). Furthermore, MHO 
and M141 are coordinately expressed at the transcript and protein levels (59, 61). 
Finally, pM140 protects pM141 from degradation in a concentration-dependent manner 
as shown above. To test this hypothesis we took advantage of two of the pM140 mutants, 
pl40DSM4/TOPO and pl40DSM3/TOPO that exhibited significantly reduced binding to 
pM141 from the GST pulldown assays (Fig. 18). The mutant constructs were subcloned 
so that they would be expressed as FLAG-epitope-tagged proteins (Fig. 34) and then each 
of the plasmids was individually titrated into RVA140-infected fibroblasts to determine 
whether they retained an ability to stabilize the pM141 protein. Although expression of 
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FIG. 34. Diagram of the panel of pM140 C-terminal deletion mutants screened for an ability to stabilize 
pM141. Full-length pM140 is shown at the top along with the location of the US22 Motifs (filled blocks) 
and the acidic domain (AD). The ruler is shown for reference with each tick mark corresponding to 10 
amino acids. Each pM140 C-terminal deletion mutant is shown drawn to scale with the location of the 
FLAG epitope tag (not drawn to scale). 
each of the truncated proteins increased with increasing amounts of transfected plasmid, 
neither one of the mutants was able to stabilize pM141 (Fig. 35). These data were 
consistent with our hypothesis that pM141 stability is conferred by 
pM140 binding. The inability to stabilize pM141 was not due to decreased expression of 
the mutant proteins since each of the truncated pM140 products was expressed to a higher 
level than pFLAG140FL when a comparable quantity of plasmid was used for 
transfection. The viral protein, ml42 (pml42), was used as a control to demonstrate that 
all transfected cells were infected at a comparable level since pml42 levels are not 
influenced by pM140 (unpublished data). 
Given these results we next asked whether the pM140 truncation mutants were 
able to complex with pM141 in transiently-transfected cells since the mutants had only 
previously been tested in in vitro assays. To perform these experiments we transfected 
each of the mutants or full-length pM140 into RVA140-infected fibroblasts and then 
immunoprecipitated the cell lysates with anti-M141 antibody. The immunoprecipitates 
were then subjected to SDS-PAGE and western blotting to detect the FLAG epitope 
expressed on each of the constructs (Fig. 36). Interestingly, we found the even though 
the truncated proteins had significantly reduced binding in the in vitro assay (Fig. 18), 
each of the mutants was immunoprecipitated with pM141 to levels comparable to the 
full-length pM140 product (Fig. 36). Since pFLAG140DSM3 and pFLAG140DSM4 
retained an ability to complex with pM141 (Fig. 36), but could no longer stabilize the 





Flag140PSM3 Mock D FL^ 








Mock Flag140DSM4 FL 






FIG. 35. Steady-state levels of pM141 in the presence of increasing amounts of pFLAG140DSM3 and 
pFLAG140DSM4. NIH3T3 fibroblasts were either transfected with transfection reagent in the absence of 
plasmid (null) or were transfected with 0,1.13,2.25,4.50, or 9.00 ng of FLAG140DSM3 (A) or 
FLAG140DSM4 (B) and 9.00 ng of FLAG140FL as a positive control as indicated. Approximately 48 
hours later the transfected cells were infected with 2 PFU/cell of RVA140. Cells were harvested, counted, 
and normalized to cell number approximately 18 hours post-infection. Shown is western blot analysis of 
lysates after SDS-PAGE. The blot was probed with antibodies to detect pM141 (top) and actin as a loading 
control (bottom) after which the blot was reprobed with either anti-M140 antibodies or anti-ml42 
antibodies as indicated. 
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FIG. 36. Anti-M141 immunoprecipitations of RVA140-infected cell lysates transiently-expressing 
pFLAG140FL (top), pFLAG140DS3 (middle), or pFLAG140DSM4 (bottom). NIH3T3 cells were 
transfected with either FLAG140FL, FLAG140DSM3, or FLAG140DSM4. Approximately 48hours later 
the cells were infected with 2 PFU/cell of RVA140 or were mock infected where indicated. Cell lysates 
were harvested approximately 18hours later and the lysates were either loaded directly on SDS-PAGE 
(lysate) or were first subjected to immunoprecipitations with anti-M141 or preimmune sera as shown. 
Displayed is the western blot probed with anti-FLAG antibody to detect the FLAG epitope fused to each of 
the constructs. 
The results from Fig. 35 revealed that a region proximal to the C terminus of 
pM140 was strictly required to protect pM141 from degradation. We wanted to map the 
boundary of pM140 are required to protect pM141 from degradation. Therefore, we 
tested the adjacent mutant, 140USAcidic/HisC, in our stability assay after the construct 
had been subcloned as a FLAG-epitope fusion, pFLAG140USAcidic (Fig. 37). The 
mutant was titrated into NIH3T3 cells using increasing amounts of the 
FLAGHOUSAcidic-expressing plasmid after which the cells were subsequently infected 
with RVA140. Steady-state levels of pM141 were assessed by Western blot analysis of 
cell lysates. We found that the mutant was expressed to levels comparable to the full-
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length protein. As the levels of pFLAG140USAcidic increased so did the levels of 
pM141 expressed from the infected cells (Fig. 37A). Upon quantitation of pM141 levels 
after normalization to the loading control (actin) it was clearly evident that 
pFLAG140USAcidic was able to stabilize pM141 to levels similar to the full-length 
protein (Fig 37B). These results demonstrate that the region of pM140 that is required to 
stabilize pM141 lies within amino acids 306-380. 
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FIG. 37. Steady-state levels of pM141 in the presence of increasing amounts of pFLAG140USAcidic. 
NIH3T3 cells were transfected with either transfection reagent in the absence of plasmid (null), 9.00 jig of 
FLAG140FL (140FL), or with 0, 1.13, 2.25, 4.50, or 9.00 ug of FLAG140USAcidic (140USAcidic). 
Approximately 48hours later the cells were infected with 2 PFU/cell of RVA140 where indicated and then 
approximately 18hours later the cells were harvested, counted, and normalized to cell number. A. Western 
blot analysis of lysates subjected to SDS-PAGE after the blot was probed for pM141 (top) and actin 
(bottom). The blot was subsequently reprobed to detect pM140 (middle panel). B. M141 protein levels 
were normalized to levels of actin and the quantitation is shown in relative units. 
Discussion 
Degradation of pM141 is enhanced in the absence of pM140 (61) suggesting that 
appropriate levels of pM141 are required for proper protein function. We have now 
demonstrated at least one mechanism by which pM141 is degraded. The data indicate 
that pM141 is degraded via the proteasomal pathway in two independent cell types. 
It is possible that pM141 is degraded by other mechanisms in addition to the 
proteasome. Although we have demonstrated that pM141 degradation is proteasome-
dependent, pM141 levels in the presence of proteasome inhibitors from RVA140 infected 
cells never reached levels like those found in WT-infected cells regardless of whether 
proteasome inhibitor was added. The most likely explanation for these findings is that 
pharmacological inhibition of the proteasomal activity is incomplete. Alternately, pM141 
may also be degraded by a second mechanism. We did not examine alternate 
mechanisms of protein degradation, but it would be of interest to see if pM141 is also 
degraded by lysosomal enzymes or by autophagy. 
We have demonstrated that proteasomal degradation of pM141 is ubiquitin-
independent. The most well-studied mechanism by which proteins are targeted to the 
proteasome is by ubiquitin tagging. However, numerous cellular (69, 77, 128) and viral 
proteins (109, 187, 202) have been shown to be degraded by the proteasomes in an 
ubiquitin-independent fashion. Although ubiquitin-independent mechanisms are less 
well understand at this time, it appears that proteins containing unstructured regions may 
be directed to the proteasome (4, 77). Bioinformatics analysis of pM141 did reveal an 
unstructured region in the form of a PEST motif. We were unable to determine if the 
PEST domain is required to target pM141 for degradation. In order to do this we would 
need to compare half-lives of pM141 constructs that contain or are deleted of the PEST 
motif and are expressed from transiently transfected cells. Unfortunately, transiently-
transfected full-length pM141 is significantly more stable than pM141 expressed from 
infected cells despite the fact that degradation of transiently-transfected pM141 is also 
proteasome-mediated. This was the case even when transiently-transfected M141 was 
expressed from its native promoter and the pM141 construct was expressed in the 
absence or presence of infection. 
We have found that direct complexing between pM140 and pM141 is not 
sufficient to stabilize pM141. We previously found that in addition to forming a larger 
complex with the MCMV pM139, a separate complex composed of only pM140 and 
pM141 is found in infected cells (82). Furthermore, we have shown that the half-life of 
pM141 is reduced in the absence of pM140 while the half-life is similar to WT levels in 
the absence of pM139 (61). Based on this evidence we hypothesized that binding of 
pM140 to pM141 restricted access to a degradation signal or otherwise stabilized the 
protein. In our current study, we found that although pM140 stabilizes pM141 in a 
concentration-dependent fashion, complexing between the proteins is not sufficient to 
protect pM141 from degradation. These results imply that there may a third binding 
partner that is recruited to the complex through pM140 and this protein stabilizes pM141 
directly. At present, we have identified two pM140 binding partners, MCMV pM139 and 
an unknown protein of 98kDa. Our previous data implies that pM139 is not able to 
stabilize pM141 since the half-life of pM141 is similar in the presence or absence of 
pM139 (61). Several experiments that are ongoing would allow us to test the hypothesis 
that an additional pM140 binding partner is required to stabilize pM141. First, we are in 
the process of trying to identify the 98kDa protein. In addition, we are attempting to 
identify other binding partners of pM140. 
Another explanation of these results is that stabilization of pM141 is dependent on 
the conformation of pM140. In this scenario, the pM140 mutants that retain an ability to 
bind to pM141 might not be able to fold in a way that allows the pM141 degradation 
signal to be masked. There is additional evidence that this region of pM140 may be 
important for proper conformation. This region was also found to contain the interaction 
domain of pM140 required for complexing with pM141 using in vitro translated pM140 
with GST pulldowns of GST141FL (see chapter HI). Interestingly, we found that the 
same pM140 deletion mutants that displayed significantly reduced binding to pM141 
using in vitro assays (Chapter HI) were able to bind pM141 to levels comparable to the 
full-length protein when the constructs were co-expressed in transiently-transfected cells 
(Chapter V). These results imply that mutants deleted of this region can only reach the 
proper conformation for pM141 binding under certain conditions (i.e. in the presence of 
intact cells). Similarly, it is possible that mutants deleted of this region may not be able 
to acquire the proper conformation to stabilize pM141 and that additional amino acids are 
required for this function. 
We have determined the specific region of pM140 required to stabilize pM141. 
Interestingly, this region, between amino acids 306 and 380, does not contain any of the 
US22 motifs or the acidic domain of MHO. Furthermore, this region of the protein does 
not share any significant sequence homology to the HCMV homologue, US23. 
M140 has been shown to regulate the degradation of other MCMV proteins 
including the major capsid protein (MCP) and the tegument protein, M25 (60). Similar to 
the results seen with pM141, steady-state levels of MCP and M25 are significantly 
reduced in RVA140-infected cells relative to that of WT-infected cells and the half-life of 
the MCP is reduced in the absence of pM140 (60). However, unlike our results with 
pM141, regulation of MCP and M25 proteins levels by pM140 have been demonstrated 
to be cell type specific. Levels of MCP and M25 protein are reduced specifically in 
macrophage cells, but not in fibroblasts. Interestingly, we have demonstrated that 
proteasomal degradation of pM141 is cell type independent. Since pM140 has a function 
in macrophage tropism it seems likely that regulation of the MCP and M25 protein levels 
in macrophages may be related to the specific function of the protein while regulation of 




The M140 and M141 proteins form a stable complex inside infected cells (82). 
We wanted to determine if the proteins function in macrophage tropism as a complex or 
as individual proteins. Thus, we attempted to map interaction domains of the proteins 
with the long term goal of generating MCMV with an interaction-defective allele. We 
were unable to map the interaction domain(s) of pM141 using a strategy of in vitro 
expression of the protein. We found that the protein, expressed in vitro, appeared to be 
globular in nature and bound non-specifically to pM140 and to our negative controls. 
Since we have successfully demonstrated specific complexing between pM141 and 
pM140 from transiently-expressed proteins, we will use a strategy of transient expression 
of the proteins in cultured cells for future experiments to map the interaction domain(s) of 
pM141. 
In the present study we were able to identify an interaction domain at the extreme 
N terminus of pM140 expressed in vitro. The amino acids in this region do not contain 
any of the US22 motifs and exhibit a fairly even distribution of polar and nonpolar 
residues. In future studies we will determine if the identified region of pM140 is required 
for complexing with pM141 when the proteins are expressed transiently in cultured cells. 
If the region is strictly required for complexing of proteins expressed under native 
conditions then we will generate a MCMV mutant with a pM140 interaction-defective 
allele to determine if pM140/pM141 complexing is required for optimal viral replication 
inside cultured macrophages or macrophage-dense organs from infected mice. 
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The M141 protein is localized diffusely throughout the cytoplasm and, to a lesser 
extent, the nucleus while pM140 is localized predominantly to the nucleus (61, 82). 
However, when the proteins are co-expressed they co-localize to a perinuclear region 
adjacent to aggresomes (60, 82). We hypothesized that pM141 contains a NLS and NES 
and relocalizes pM140 from the nucleus to the perinuclear locale and we wanted to 
determine where the protein functions. Thus, we wanted to map the localization signals 
of pM141 with the long term goal of generating MCMV with alleles defective in M141 
localization domains. Using a strategy of increasing deletions at each terminus of 
pM141, we were unable to determine if the protein contains a functional NLS or NES. 
Future experiments to map the localization domain(s) of pM141 will examine specific 
protein subdomains fused to a neutral protein that contains no localization signals and is 
also small enough to enter the nucleus by passive diffusion such as GFP. The 
localization of each fusion protein will be assessed to determine if the protein domain 
contains a specific subcellular localization signal. 
In the absence of pM140 steady-state levels of pM141 are significantly decreased 
and the half-life of pM141 is reduced from approximately 2 hours to 1 hour (61). We 
wanted to determine the mechanism of pM141 degradation and assess the contribution of 
pM140 in protecting the protein from degradation with the long term goal of 
understanding how regulation of pM141 by pM140 contributes to the function of the 
proteins. In the present study we determined that pM141 degradation is proteasome-
dependent, but ubiquitin-independent. Due to the fact that transiently-expressed pM141 
is significantly more stable than pM141 expressed from infected cells, we were unable to 
map the degradation signal of the protein using a strategy of deletion analysis with 
pM141 constructs that were designed to express proteins transiently in cultured cells. 
However, we were able to determine that stability of pM141 is dependent on the 
concentration of pM140. We were able to map the region in pM140 required to stabilize 
pM141. Interestingly, the region does not contain US22 motifis or the pM140 acidic 
domain and it does not overlap with a pM141 interaction domain demonstrating that 
direct complexing between the proteins is not sufficient to protect pM141 from 
degradation. These results suggest a model (Fig. 38) where pM141 can be targeted for 
degradation even when pM140/pM141 complexing can occur. However, under native 
conditions pM140 recruits a third protein of unknown origin to the complex and this 
protein prevents rapid degradation of pM141. In future studies we will map the 
degradation signal of pM141 by generating mutations in the M141 gene in mutant 
MCMV. We will also compare viral titers in infected cultured macrophages and 
macrophage-dense organs from infected mice of WT MCMV, RVA140, and a MCMV 
mutant expressing pM140 that is unable to stabilize pM141. 
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FIG. 38. Model of regulation of pM141 stability by pM140. The M141 protein can be targeted for 
degradation by the proteasome (blue cylinder) under circumstances where pM140 and pM141 can form a 
complex (left). However, inside WT infected cells pM140 recruits an, as yet unidentified, third protein to 
the pM140/pM141 complex that is able to directly stabilize pM141 and prevents its rapid degradation 
(right). The location of the nucleus and cytoplasm are shown. 
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